Injection Force Measurement: A Critical Guide for Drug Delivery System Development

Lily Turner Dec 02, 2025 432

This article provides a comprehensive overview of injection force measurement, a critical parameter in the development of patient-centric drug delivery systems.

Injection Force Measurement: A Critical Guide for Drug Delivery System Development

Abstract

This article provides a comprehensive overview of injection force measurement, a critical parameter in the development of patient-centric drug delivery systems. Covering foundational principles, advanced methodologies, and optimization strategies, it addresses the challenges posed by high-viscosity biologics and complex formulations like microparticles. The content synthesizes current standards, predictive modeling, and human factors to guide researchers and scientists in ensuring device performance, dosing accuracy, and patient comfort from development through real-world use.

Understanding Injection Force: Principles, Parameters, and Impact on Drug Delivery

In the development of parenteral drug products, particularly those packaged in prefilled syringes (PFS) and autoinjectors, the mechanical forces required for administration are critical quality attributes that directly impact patient safety, dosing accuracy, and product usability. These force metrics—break-loose force, glide force, and maximum force—serve as essential performance parameters that ensure drug delivery systems function as intended across diverse patient populations, including those with conditions like rheumatoid arthritis that may impair hand strength [1].

The global injectable drug delivery market, anticipated to grow from US$690.23 billion in 2025 to over US$1,034.78 billion by 2030, reflects increasing reliance on these delivery systems, driven particularly by the rise of biologics and chronic disease treatments [2]. Within this expanding market, understanding and controlling injection forces has become paramount for product development teams seeking to balance physical constraints with therapeutic efficacy. This guide provides a comparative analysis of these key force metrics across different delivery systems, supported by experimental data and standardized testing methodologies essential for researchers and drug development professionals.

Defining the Key Force Metrics

Break-Loose Force

Break-loose force (also known as initiating force or plunger-stopper break-loose force) is defined as the maximum force required to dislodge the plunger from its static position within the syringe barrel [3] [4]. This force represents the static friction that must be overcome to initiate plunger movement. In practical terms, excessive break-loose force can lead to difficult injection initiation, potentially causing sudden plunger movement once static friction is overcome, which may compromise dosing accuracy [3].

Glide Force

Glide force (also referred to as sustaining force or dynamic glide force) is the force required to maintain plunger movement once static friction has been overcome [3] [4]. This dynamic force maintains consistent medication delivery throughout the injection process. The glide force is typically calculated as the average force measured during the plunger travel after the initial break-loose event, excluding the break-loose peak [3] [5].

Maximum Force

Maximum force (Fmax) represents the highest force measured during plunger travel before the plunger finishes its course at the front end of the syringe [5] [4]. This parameter is particularly critical for high-viscosity formulations where forces may increase toward the end of the injection stroke due to increased pressure requirements. For some measurements, the break-loose force is recorded as the "first Fmax," with subsequent peaks representing the true maximum force during medication expulsion [4].

Table 1: Summary of Key Force Metrics in Injection Performance

Force Metric Alternative Terms Definition Functional Significance
Break-Loose Force Initiating force; Plunger-stopper break-loose force (PBF) Maximum force required to initiate plunger movement from static position Impacts injection initiation ease; excessive force may cause jerky plunger movement
Glide Force Sustaining force; Dynamic glide force (DGF) Average force required to maintain plunger movement after initiation Affects smoothness of medication delivery and injection control throughout process
Maximum Force Fmax Highest force measured during entire plunger travel until injection completion Critical for high-viscosity formulations; must not exceed patient capability

Standardized Testing Methodologies

Equipment and Instrumentation

The measurement of injection forces requires precise instrumentation capable of capturing force profiles with high accuracy. Universal testing machines (UTMs) from manufacturers such as Instron and ZwickRoell are widely employed with custom-designed syringe fixtures [3] [6]. These systems typically utilize load cells with capacities appropriate for the expected force ranges (e.g., 100N or 50N for standard syringes), with high-accuracy models meeting ISO 7500-1 accuracy class 0.5 standards (±0.5% accuracy) [4].

The test fixtures are designed to accommodate various syringe geometries, with adjustable specimen holders that can be steplessly adjusted without tools. ZwickRoell's universal test fixture, for instance, supports syringes with diameters of 5-50 mm and lengths of 30-150 mm, with optional holders for specimens without finger grips [6]. For compliance with regulatory requirements, particularly in pharmaceutical applications, software solutions like testXpert III provide traceable, tamper-proof test results in accordance with FDA 21 CFR Part 11 [6].

Standardized Test Protocols

The International Organization for Standardization (ISO) provides several critical standards governing injection force measurement. ISO 7886-1 regulates the mechanical properties and specifications of hypodermic syringes, while ISO 11608-3 outlines requirements for needle-based injection systems [3] [6]. More recently, ISO 11040-4 has been implemented for prefilled syringes, with Annex E providing specific methodology for documenting maximum glide force [4].

A typical test procedure involves:

  • Mounting the syringe in the universal testing machine fixture
  • Carefully removing the needle shield while maintaining syringe orientation
  • Initiating data collection when the load cell contacts the plunger head
  • Pushing the plunger through the syringe at a constant speed (typically 50 mm/min for 18.2 mm travel)
  • Measuring force in newtons throughout the plunger displacement [4]

During analysis, break-loose force is automatically determined as the maximum force observed during the initial 0-2 mm of plunger travel, while glide force is calculated as the average force during the subsequent 2-18.2 mm range [4]. This standardized approach ensures consistency across different testing scenarios and enables valid comparative assessments.

Comparative Experimental Data

Syringe Size and Needle Gauge Comparisons

Research has demonstrated significant variations in force metrics across different syringe-needle combinations. A comprehensive study measuring initial and maintenance forces across syringe sizes (1mL to 20mL) paired with various needle gauges (26G to 30G) revealed substantial differences in performance characteristics [7].

Table 2: Break-Loose and Glide Force Measurements Across Syringe-Needle Combinations

Syringe Size Needle Gauge Break-Loose Force (N) Glide Force (N) Performance Notes
1 mL 26G (Original) 1.15 (±0.22) 0.13 (±0.05) Lowest overall forces; optimal for sensitive applications
1 mL 27G 0.87 0.32 Moderate force increase with smaller gauge
1 mL 30G 0.80 0.71 Significant glide force increase despite smaller break-loose
3 mL 23G (Original) 4.95 (±0.35) 2.15 (±0.12) Balanced performance for standard applications
5 mL 22G (Original) 12.84 (±1.02) 14.21 (±0.45) Noticeable force increase with larger syringe volume
10 mL 21G (Original) 18.50 (±1.87) 25.33 (±1.15) Highest forces; requires significant thumb pressure

The data reveals that the 1mL syringe with its original 26G needle demonstrated the lowest maintenance force (0.13N), making it particularly suitable for applications requiring precise control [7]. Conversely, the combination of a 10mL syringe with a 30G needle produced the highest initial and maintenance forces, potentially challenging for patients with limited hand strength.

Formulation Viscosity and Injection Force Relationships

Formulation viscosity represents one of the most significant factors influencing injection forces, particularly glide force and maximum force. Research has established clear correlations between viscosity and force requirements, with implications for injectability across different patient populations [5] [1].

Table 3: Impact of Formulation Viscosity on Injectability Force Requirements

Formulation Type Viscosity Range Maximum Force (Fmax) Injectability Assessment Suitable Patient Population
Low-viscosity solutions < 10 cP < 50 mPa Smooth, easy injection All patients, including children and elderly
Medium-viscosity formulations 10-50 cP 50-125 mPa Feasible with minimal difficulty Most adults without hand strength limitations
High-viscosity biologics 50-100 cP 125-160 mPa Moderate difficulty Adults with normal hand strength
Very high-viscosity concentrates > 100 cP 160-250 mPa Difficult to very difficult Limited to patients with good hand strength
Extremely viscous formulations > 200 cP > 250 mPa Practically impossible Not suitable for manual injection

Studies have proposed specific injectability thresholds based on human factor assessments. According to this classification, injections requiring Fmax values up to 125 mPa proceed smoothly, while forces between 125-160 mPa remain feasible though with some difficulty. Forces exceeding 160 mPa become progressively more challenging, with those above 250 mPa considered practically impossible for manual administration [5].

Advanced Needle Technologies

Innovations in needle design have emerged to address challenges associated with high-viscosity formulations. Tapered needle technology represents one such advancement, demonstrating improved performance characteristics compared to conventional thin-wall needles [8].

Research comparing 29G tapered needles (29G TNN) with conventional 27G thin-wall (27G TW) and 29G thin-wall (29G TW) needles using various protein solutions revealed distinct advantages for shear-thinning formulations. The injection forces measured in 29G TNN prefilled syringes were lower than those in 29G TW for all solutions tested, and similar to those in 27G TW PFSs for Newtonian solutions [8]. Most notably, for non-Newtonian solutions demonstrating shear-thinning behavior, the tapered needles produced lower injection forces than the 27G TW needles, highlighting their particular utility for complex biologics [8].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Essential Materials and Equipment for Injection Force Research

Item Function/Application Representative Examples
Universal Testing Machine (UTM) Measures force with high accuracy during plunger displacement Instron 5940 Series; ZwickRoell zwickiLine
Syringe Test Fixture Holds syringe in optimal position for force application ZwickRoell universal test fixture with adjustable specimen holder
High-Accuracy Load Cell Precisely measures injection forces in newtons 100N or 50N capacity load cells (ISO 7500-1 Class 0.5)
Texture Analyzer Alternative instrument for injection force measurement Stable Micro Systems TA.XTplus
Prefilled Syringes Test articles for combination product assessment 1mL long borosilicate glass syringes with staked-in needles
Needle Variants Assessing impact of needle geometry on injectability Tapered needles (Terumo); Thin-wall needles; Filter needles
Model Solutions Simulating various rheological behaviors PEG solutions (Newtonian); CMC solutions (shear-thinning)
Protein Formulations Representative biopharmaceutical products Monoclonal antibodies at various concentrations
Data Acquisition Software Controls test parameters and records force profiles testXpert III; Bluehill Universal
Statistical Analysis Package Processes and compares force measurement data JMP SAS; Origin

The systematic measurement and optimization of break-loose, glide, and maximum forces represent a critical aspect of injectable drug product development, directly impacting patient experience, dosing accuracy, and ultimately therapeutic outcomes. As the data demonstrates, these force metrics vary significantly across different delivery systems, influenced by factors including syringe size, needle gauge, and formulation viscosity.

For researchers and drug development professionals, the standardized methodologies and comparative data presented provide a framework for evaluating injection performance across different product configurations. The continuing evolution of needle technologies and formulation strategies offers promising pathways for addressing the challenges posed by high-viscosity biologics, particularly through innovations such as tapered needles that demonstrate advantages for shear-thinning formulations.

As the injectable drug delivery market continues its expansion, driven increasingly by biologics and patient-self-administration trends, the precise characterization and optimization of these fundamental force metrics will remain essential to developing products that are not only therapeutically effective but also practically usable across diverse patient populations.

In the development of parenteral drug products, particularly biologics and high-concentrated formulations, syringeability and injectability are critical performance parameters that directly impact patient experience and treatment efficacy. Though often used interchangeably, these terms describe distinct aspects of the delivery process. Syringeability refers to the ease of withdrawing a solution from its container into the syringe, encompassing factors such as ease of withdrawal, clogging and foaming tendencies, and accuracy of dose measurements [5] [9]. Injectability, conversely, is "a term related to the ease of parenteral administration of a dosing solution, and includes dose preparation, dose administration, ergonomics related to these procedures, pain of injection, and other adverse events at the injection site" [9] [10]. Both parameters are profoundly influenced by a complex interplay between formulation properties (especially viscosity), needle geometry, and the specific characteristics of the delivery system [5] [10].

Understanding these factors is particularly crucial for modern biopharmaceuticals, where highly concentrated protein solutions often exhibit elevated viscosities that challenge traditional delivery approaches [11]. The performance of the needle-syringe-formulation system must be thoroughly characterized during product development to ensure both patient comfort and accurate dosing, especially for self-administered therapies where users may have functional impairments [10]. This guide objectively compares how critical factors influence injectability performance, supported by experimental data and standardized testing methodologies from current research.

The Critical Role of Viscosity and Rheology

Viscosity, defined as a fluid's resistance to flow, stands as the primary formulation property affecting injectability. While simple aqueous solutions may have viscosities similar to water (~1-5 cP), concentrated biologics often exhibit viscosities ranging from 10-200 cP, with some formulations reaching much higher values [11]. This increased viscosity directly translates to greater injection forces, potentially compromising patient ability to complete injections, particularly in self-administration scenarios.

The relationship between viscosity and injection force can be described theoretically for Newtonian fluids using a form of the Hagen-Poiseuille equation: [ F = \frac{128 Q L \mu A}{\pi D^4} ] Where F is the plunger force (N), Q is the volumetric flow rate (m³/s), μ is the dynamic viscosity (Pa·s), L is the needle length (m), D is the needle diameter (m), and A is the syringe plunger area (m²) [11]. This equation highlights the direct proportionality between viscosity and the required injection force.

However, many biological formulations exhibit non-Newtonian behavior, particularly shear-thinning, where viscosity decreases under the high shear rates experienced during injection [10]. The shear rate in a needle during injection can reach approximately 100,000 s⁻¹ [10], making the rheological characterization at these conditions essential for accurate injectability prediction. For shear-thinning fluids, the relationship becomes more complex: [ F = \frac{2K L A}{Rs^2} \left( \frac{Q(3+1/n)}{\pi Rn^3} \right)^n ] Where K is the consistency index (Pa·sⁿ), n is the power index (-), Rs is the syringe radius (m), and Rn is the needle radius (m) [12].

Table 1: Clinical Injectability Thresholds Based on Maximum Force (Fmax)

Maximum Force (Fmax) Injectability Assessment Clinical Experience
Up to 125 mPa Injection smooth Easy administration
125-160 mPa Feasible with some difficulty Moderate difficulty
160-250 mPa Very difficult Challenging for patients
Above 250 mPa Practically impossible Not administrable

Data derived from panel tests correlating force measurements with manual injection experiences [5]

The table above provides crucial thresholds derived from empirical research correlating measured injection forces with human injection experiences. These values serve as important guidelines during formulation development to ensure the final product falls within an acceptable force range.

Impact of Needle Geometry on Injection Performance

Needle geometry represents another critical factor significantly impacting injectability, particularly with high-viscosity formulations. The two most important geometric parameters are needle inner diameter (gauge) and needle length, both of which directly influence the pressure drop required to achieve flow through the needle.

Research has consistently demonstrated that reducing needle diameter substantially increases the force required for injection. This relationship follows the inverse fourth-power relationship with diameter described in the Hagen-Poiseuille equation, making it an extremely sensitive parameter [11]. Similarly, increasing needle length elevates injection force proportionally, though with a less dramatic effect than diameter changes. One study investigating high-concentrated suspensions found that increasing needle inner diameter considerably reduced clogging risk, while increasing vehicle viscosity, particle size, and tissue backpressure significantly increased clogging [13].

The clinical preference for thinner needles (higher gauge) to reduce injection pain creates a fundamental tension with injectability requirements. Patients frequently use pen injectors with 29-31-G needles, while pre-filled syringes for subcutaneous dosing commonly employ 27-G and 25-G needles [5]. This trade-off between patient comfort and injection practicality must be carefully balanced during product development.

Table 2: Needle Geometry Effects on Injectability and Clinical Application

Needle Size (Gauge) Inner Diameter (mm) Typical Application Injectability Considerations
21-23 G 0.51-0.33 Intramuscular, viscous formulations Lower resistance, suitable for high-viscosity drugs
25-27 G 0.26-0.21 Standard subcutaneous Balance between comfort and injectability
29-31 G 0.18-0.13 Pen injectors, diabetes care Highest resistance, limited to low-viscosity solutions

Data compiled from multiple sources on needle geometry and clinical applications [5] [9]

Beyond diameter and length, other geometric factors including needle wall finish, point geometry (number of bevels), and taper design can influence penetration force and injection flow characteristics. One study noted that a modified 5-bevel needle tip was perceived as less painful and was preferred by subjects following home use for usual injections [14].

Formulation Characteristics and Their Effects

Formulation characteristics extend beyond simple viscosity to encompass a range of properties that significantly influence injectability. Particle-based systems (suspensions, microspheres, liposomes) introduce additional challenges, primarily related to potential clogging and flow instability. The physical interaction between the solid phase (particles), the vehicle (flow field), and injection devices could result in the formation of particle bridging or filtering, posing a major risk in dose delivery accuracy and injectability [13].

For suspensions, particle characteristics including size, shape, concentration, and surface properties dramatically impact injectability. Research has demonstrated that increasing particle concentration and size significantly increases clogging risk, while spherical particles typically flow more readily than irregular shapes [13]. In high-concentration suspensions, phenomena such as shear thickening at high shear rate regions, particle bridging over the needle entrance, and eventual needle clogging can occur [13].

The vehicle properties in dispersed systems also critically influence injectability. Aqueous versus oily bases, surfactant content, and rheological modifiers all contribute to the overall injection experience. For example, thixotropic formulations that decrease in viscosity under shear stress can significantly improve injectability by reducing the required injection force once flow is initiated [11].

Table 3: Formulation Types and Their Injectability Challenges

Formulation Type Typical Viscosity Range Primary Injectability Challenges Mitigation Strategies
Aqueous solutions 1-10 cP Minimal, primarily affected by viscosity Concentration optimization
Protein solutions 10-200 cP High viscosity, shear sensitivity Excipient screening, shear-thinning design
Suspensions Variable Particle clogging, settling, filter pressing Particle size control, viscosity modification
Emulsions 10-100 cP Phase separation under shear Emulsifier optimization, viscosity adjustment
Gels/Semi-solids 100-10,000+ cP High injection force, non-Newtonian flow Thixotropy, pre-filled syringes

Data synthesized from characterization studies of various formulation types [5] [11]

The development of complex biologics has introduced additional formulation challenges. These molecules often exhibit concentration-dependent viscosity due to reversible self-association and electrostatic interactions, sometimes resulting in exponential viscosity increases with concentration [11]. This behavior necessitates careful characterization during formulation development to identify concentration thresholds where injectability becomes problematic.

Experimental Protocols for Injectability Assessment

Mechanical Testing Method

The quantification of injectability through mechanical testing provides objective, reproducible data for comparing formulations and delivery systems. The standard protocol utilizes a mechanical tester (texture analyzer) equipped with an appropriate load cell (typically with a maximum load of 200 N) to compress the syringe plunger at a controlled rate while measuring the required force [12] [15].

The basic experimental workflow consists of:

  • Sample Preparation: Formulations are prepared according to their intended clinical preparation method and loaded into syringes, either in advance for stable formulations or immediately before testing for time-dependent materials [12].
  • Instrument Setup: The mechanical tester is equipped with flat platens and calibrated. A pre-load of 0.5 N is typically set, with a pre-load speed of 5 mm/min and test speed of 1 mm/s for a standard 5 mL syringe [12].
  • Clamping System: The syringe is securely positioned in a fixture that aligns it with the crosshead while allowing collection of extruded material [12].
  • Testing Execution: The crosshead descends at the predetermined rate until the pre-set displacement or force limit is reached, continuously recording force versus displacement data [12].

Key parameters extracted from the force-displacement curve include:

  • Plunger-stopper breakloose force (PBF): The force required to initiate plunger movement [5]
  • Maximum force (Fmax): The highest force measured during plunger travel [5]
  • Dynamic glide force (DGF): The force required to sustain plunger movement [5]
  • Total work done (WT): The area under the force-displacement curve, representing the total energy required for complete extrusion [11]

G Start Sample Preparation A Load Sample into Syringe Start->A B Attach Needle A->B C Position in Mechanical Tester B->C D Set Test Parameters: - Pre-load: 0.5 N - Speed: 1 mm/s - Force Limit: 200 N C->D E Begin Compression Test D->E F Record Force-Displacement Data E->F G Extract Key Parameters: - Breakloose Force (PBF) - Maximum Force (Fmax) - Dynamic Glide Force (DGF) - Total Work (WT) F->G H Data Analysis G->H

Experimental Workflow for Injectability Testing

Advanced Characterization Techniques

For complex formulations, particularly suspensions, more advanced characterization techniques may be necessary. One innovative approach establishes a custom fluorescence tagging and imaging technique with integrated force sensors to enable visual observation of local particle concentrations and plunger force monitoring throughout injection [13]. This method allows researchers to correlate force spikes with specific particle behaviors such as bridging or clogging.

Another specialized approach involves testing injection into ex vivo tissue to account for tissue backpressure, which can significantly impact injection forces, particularly for subcutaneous administration [5] [13]. One study specifically evaluated the force required to inject formulations into human subcutaneous tissue obtained from cosmetic surgery procedures, providing more clinically relevant data than injection into air [5].

For formulations exhibiting time-dependent properties (such as setting cements or thermosensitive gels), the testing protocol must account for temporal changes. One study on thermosensitive, low-concentrated chitosan colloids found that reducing the needle diameter and increasing its length and the crosshead speed increased the injection forces [14], highlighting the importance of evaluating injectability under relevant conditions.

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 4: Essential Materials for Injectability Assessment

Category Specific Items Function/Application
Testing Equipment Texture Analyzer/Mechanical Tester Measures injection force with controlled displacement
Load Cells (5-N to 200-N capacity) Captures force data across expected range
Capillary Viscometer/Rheometer Characterizes formulation viscosity
Delivery Components Syringes (Various volumes, Luer Lock) Standardized delivery platform
Needles (Various gauges: 21G-31G) Assess geometry impact
Pre-filled Syringe Systems Simulate commercial presentation
Test Materials Polymer Solutions (PEO, HPMC) Viscosity standards and model systems
Model Particles (Glass spheres) Suspension behavior studies
Ex Vivo Tissue Samples Tissue backpressure assessment
Specialized Tools Fluorescence Tagging System Visualizes particle flow and distribution
High-Speed Camera Documents flow instabilities and clogging
Data Acquisition Software Records and analyzes force-time-displacement

Toolkit compiled from methodologies described across multiple experimental studies [5] [13] [12]

Injectability represents a critical quality attribute for parenteral drug products, particularly as formulations grow more complex and concentrated. Through systematic assessment using standardized mechanical testing protocols, researchers can quantify how viscosity, needle geometry, and formulation characteristics collectively influence injection performance. The experimental data and comparative information presented in this guide provide a framework for making informed decisions during product development, balancing the competing demands of stability, efficacy, and patient experience. As biopharmaceuticals continue to advance, robust injectability assessment will remain essential for successful drug development and optimal patient outcomes.

For researchers and drug development professionals, the concept of 'injectability' represents a critical interface between pharmaceutical formulation and patient experience. Injectability encompasses the performance of a suspension during injection, including factors such as the pressure or force required for injection, evenness of flow, and freedom from clogging [16]. As drug delivery systems (DDS) grow more sophisticated—evolving from simple solutions to complex microparticles, liposomes, and nanoparticles—understanding and optimizing injectability has become paramount for ensuring both therapeutic efficacy and patient compliance [16] [17].

The rising prevalence of chronic diseases requiring frequent injection, particularly in oncology, diabetes, and rheumatology, has intensified focus on patient-centric drug delivery design [18] [19]. While substantial research investment has targeted the development of novel drug carriers with enhanced therapeutic performance, the practical administration challenges of these systems have often been overlooked [16]. This review establishes the critical relationship between injection force parameters and patient-reported experience, providing comparative experimental data and methodologies to guide future development of patient-friendly injection systems.

Quantifying Injectability: Key Parameters and Measurement Methodologies

Core Injectability Metrics

Injectability evaluation revolves around two primary quantitative metrics: injection force (the force required during injection administration) and discharge rate (the actual percentage of microparticles successfully transferred through the injection system) [16]. Both parameters directly impact the clinical usability and reliability of injectable formulations. Excessive injection force can lead to variable administration rates, incomplete dosing, needle clogging, and patient anxiety or self-discontinuation of treatment. Similarly, inconsistent discharge rates compromise dosing accuracy and therapeutic efficacy, particularly for potent compounds with narrow therapeutic windows [16].

Experimental Protocols for Injectability Assessment

Standardized experimental approaches have been developed to systematically evaluate injectability parameters across different formulation types:

Injection Force Measurement: Mechanical testers are employed to measure the force required to depress syringe plungers under controlled conditions. Testing typically evaluates multiple injection speeds, needle gauges, and formulation viscosities to simulate clinical administration scenarios [16].

Discharge Rate Quantification: Researchers calculate discharge rates by comparing the mass of microparticles or drug content in the initial formulation versus the mass successfully delivered through the needle assembly. This involves analytical techniques such as HPLC, UV-Vis spectroscopy, or gravimetric analysis [16].

In Vitro Clogging Tendency Evaluation: Sieve tests assess the propensity of microparticle formulations to clog needles by measuring particle retention after passage through various needle gauges. This is complemented by rheological measurements to characterize suspension flow properties [16].

In Vivo Correlation Studies: Animal models (typically rats) provide correlative data on in vitro injectability parameters versus in vivo performance, including tissue distribution, injection site reactions, and bioavailability [16].

Table 1: Standard Experimental Conditions for Injectability Testing

Parameter Standard Values/Ranges Measurement Instrumentation Key Outcome Measures
Injection Speed 1–10 mm/min Mechanical tester with force transducer Maximum force (N), mean force (N)
Needle Gauge 23G–29G Standard hypodermic needles Force variability, clogging frequency
Vehicle Viscosity 1–1000 cP Rheometer Discharge rate %, residual volume
Particle Concentration 50–300 mg/mL Analytical balance Dose accuracy, particle aggregation
Temperature 20°C (ambient), 37°C (physiological) Temperature-controlled chamber Force variation with temperature

Comparative Analysis of Injection Performance Across Delivery Systems

Microparticle Delivery Systems

Injectable microparticle systems present unique injectability challenges due to their particulate nature. A comprehensive study evaluating levonorgestrel (LNG) microspheres, glass beads, and mesoporous silica revealed significant differences in injection performance based on particle characteristics [16].

Particle size and needle gauge demonstrated the most substantial influence on injectability, with larger particle sizes and smaller needle gauges (higher gauge numbers) resulting in significantly impaired injectability. The needle gauge was identified as the single most influential factor, with 23-gauge needles providing optimal performance for microparticle suspensions at concentrations of 120-240 mg/mL with a viscosity of approximately 60 cP [16].

Table 2: Injection Force and Discharge Rate Comparison Across Particle Types

Particle Type Particle Characteristics Injection Force (N) Discharge Rate (%) Clogging Tendency
LNG Microspheres Spherical, ~50μm, smooth surface Moderate High (>90%) Low
Glass Beads Spherical, ~50μm, very smooth surface Low High (>90%) Very Low
Mesoporous Silica Irregular shape, ~50μm High Moderate (70-85%) High
Nanoparticles Spherical, <1μm Very Low Very High (>95%) Very Low
Impact of Formulation Parameters

Beyond particle characteristics, suspension medium properties significantly influence injectability. Sodium carboxymethyl cellulose (CMC-Na) vehicles demonstrated basically Newtonian behavior in the shear rate range of 0.1 s⁻¹–100 s⁻¹, with no obvious shear thinning observed at higher shear rates [16]. The viscosity of suspensions increased with rising volume fraction of particles, following established hydrodynamics principles described by the Navier-Stokes equation, Krieger-Dougherty equation, and Hagen-Poiseuille equation [16].

Vehicle viscosity and injection speed have varying effects on discharge rate and injection force, respectively. Higher viscosity vehicles typically require greater injection forces but may improve discharge rates by reducing particle settling during administration. Optimization requires balancing these competing factors for specific application requirements [16].

Patient Experience and Reporting in Injection System Design

Patient-Reported Outcomes and Injection Experience

The European Medicines Agency defines Patient-Reported Outcomes (PROs) as "a health/treatment outcome reported directly by the patient without the interpretation of a clinician or another person" [19]. PRO data are collected through validated patient-reported outcome measures (PROMs), which serve as crucial tools for capturing the patient experience of injection devices, including ease of use, pain, anxiety, and satisfaction [19].

PROs can be generic or disease-specific. Generic PROMs enable comparison across different patient populations and conditions but may lack sensitivity to specific disease-related injection experiences. Disease-specific PROMs provide more relevant and responsive data for particular conditions but limit cross-condition comparisons [19]. The systematic integration of PROs into injection system development represents a paradigm shift toward patient-centric design in pharmaceutical development.

Direct Patient Reporting in Pharmacovigilance

Legislative changes in the European Union have empowered patients, their representatives, and caregivers to directly report adverse drug reactions (ADRs), creating an additional source of drug safety information [20]. Analysis of EudraVigilance data shows that patient reporting of adverse reactions has become a substantial component of pharmacovigilance, accounting for approximately 30% of total reports annually since 2014 [20].

This direct patient reporting provides invaluable insights into real-world injection experiences, including device-specific issues that may not be captured in traditional healthcare professional reporting. The data reveals no significant interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports compared to reports from healthcare professionals, supporting the value of patient reporting across the severity spectrum [20].

Emerging Technologies and Future Directions

Advanced Control Systems for Injection Optimization

Industry 4.0 approaches are being applied to injection systems, with artificial intelligence (AI) and machine learning (ML) algorithms enabling predictive control and optimization. Research demonstrates that machine learning algorithms can effectively predict quality parameters in injection processes, with decision tree algorithms achieving over 90% accuracy even with limited training data [21].

Reinforcement learning approaches show particular promise for injection parameter optimization. Actor-critic algorithms have demonstrated the ability to optimize injection molding filling and holding phases in less than 16 injection cycles for the filling phase and less than 10 cycles for the holding phase [22]. These AI-driven methods can adapt to different products, materials, and geometries by leveraging prior knowledge, significantly reducing setup time and optimization costs [22].

Smart Drug Delivery Systems

Next-generation drug delivery systems incorporate advanced materials and technologies to enhance therapeutic performance while improving administration experience. Recent advances include red blood cell membrane-camouflaged nanoparticles, self-emulsifying systems, and stimuli-responsive materials that release drugs in response to specific physiological triggers [17] [23].

These systems aim to improve drug solubility, target site accumulation, efficacy, and pharmacological activity while reducing toxicity [17]. From an injectability perspective, many of these advanced systems offer improved flow properties and reduced injection forces compared to conventional microparticle systems, potentially enhancing the patient experience during administration.

Visualizing the Injection Force-Patient Experience Relationship

G cluster_0 Input Factors cluster_1 Mechanisms cluster_2 Patient Outcomes Formulation Formulation InjectionForce InjectionForce Formulation->InjectionForce Viscosity Particle Size Device Device Device->InjectionForce Needle Gauge Geometry Patient Patient PhysicalExperience PhysicalExperience Patient->PhysicalExperience Sensitivity Tissue Properties InjectionForce->PhysicalExperience Directly Impacts PsychologicalImpact PsychologicalImpact PhysicalExperience->PsychologicalImpact Pain Anxiety TreatmentAdherence TreatmentAdherence PhysicalExperience->TreatmentAdherence Affects PsychologicalImpact->TreatmentAdherence Influences ClinicalOutcomes ClinicalOutcomes TreatmentAdherence->ClinicalOutcomes Determines

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagents and Materials for Injectability Studies

Item Function/Application Example Specifications
Mechanical Testers Quantify injection force Standardized force measurement, variable speed control
Hypodermic Needles Evaluate gauge impact on flow 23G-29G, various lengths (0.5-1.5 inch)
Rheometers Characterize viscosity profiles Shear rate range: 0.1-100 s⁻¹, temperature control
Microparticle Systems Model particulate formulations LNG microspheres, glass beads, mesoporous silica
Sodium CMC Vehicle viscosity modifier Concentration series: 0.5-2.0% w/v
Syringe Systems Standardized administration 1-3 mL Luer-Lok compatible
In-Mold Sensors Process parameter monitoring Multivariable sensors (MVS) for pressure/temperature
Animal Models In vivo correlation studies Rat subcutaneous injection models

The critical relationship between injection force and patient experience necessitates a systematic approach to injectability optimization throughout the drug development process. Experimental evidence demonstrates that formulation parameters—particularly particle characteristics, vehicle viscosity, and needle selection—directly impact both injection performance and patient experience outcomes.

The growing emphasis on patient-centric drug development requires integration of injectability testing early in formulation development rather than as a secondary consideration. By adopting standardized methodologies for injection force and discharge rate quantification, along with systematic collection of patient-reported outcomes, researchers can significantly enhance both the clinical usability and therapeutic effectiveness of injectable drug delivery systems.

Future advances will likely incorporate real-time monitoring and AI-driven control systems to dynamically adjust injection parameters, further optimizing the patient experience while ensuring precise drug delivery. As drug delivery systems grow more complex, the fundamental relationship between injection force and patient experience will remain a critical consideration for researchers and product developers alike.

Regulatory Landscape and Essential Standards (ISO 11040, ISO 11608)

For researchers and scientists in drug delivery, navigating the regulatory and standards landscape is crucial for developing safe and effective injection systems. Two essential international standards govern this field: ISO 11040 for prefilled syringes and ISO 11608 for needle-based injection systems (NIS). These standards establish definitions, requirements, and testing criteria to ensure device quality, safety, and efficacy, and are widely referenced by regulatory bodies like the FDA [24] [25]. This guide provides a detailed comparison of their scope, testing requirements, and application within the critical context of injection force measurement research.

ISO 11040 Series: Prefilled Syringes

The ISO 11040 series specifically addresses prefilled syringes (PFS), which are disposable needle-based injection systems pre-filled with a specified drug substance [26]. The standard is divided into multiple parts covering various subcomponents:

  • Parts 1-3: Concern cartridges for local anesthetics in dental settings [27].
  • Parts 4-6: Cover subcomponents, including glass barrels (Part 4), plastic barrels (Part 6), and plunger stoppers [27] [26].
  • Part 7: Addresses packaging systems for pre-sterilized "fill and finish" applications [27].
  • Part 8: Outlines test methods and evaluation criteria for the finished syringe as an integrated system [27] [26].

Testing to ISO 11040 is critical for assessing the integrity and functionality of prefilled syringes, ensuring proper drug containment and expulsion [27] [26]. The standard mandates up to 12 unique test procedures, including glide force, break-loose force, flange breakage resistance, and Luer cone breakage resistance [27] [26].

ISO 11608 Series: Needle-Based Injection Systems

The ISO 11608 series sets the standard for how needle-based injection devices (NIS) should be designed and verified [25]. Its scope covers systems that deliver discrete volumes of a medicinal product via needles or soft cannulas through intradermal, subcutaneous, and/or intramuscular routes [25]. The series was substantially updated in 2022 and comprises seven parts:

  • -1: General Requirements: The "parent" part, establishing foundational requirements and test methods [25] [28].
  • -2: Double-Ended Pen Needles [25].
  • -3: Containers and Integrated Fluid Paths [25].
  • -4: Systems Containing Electronics [25].
  • -5: Automated Functions [25].
  • -6: On-Body Delivery Systems (OBDS) [25].
  • -7: Accessibility for Persons with Visual Impairment [25].

The standard incorporates a risk-based design approach and places greater emphasis on human factors, requiring consideration of the entire user experience [25] [28].

Direct Comparison of Standards

Table 1: Comparative Analysis of ISO 11040 and ISO 11608

Aspect ISO 11040 Series ISO 11608 Series
Primary Scope Prefilled syringes (PFS) as primary drug containers [26] Needle-based injection systems (NIS) as drug delivery devices [25]
Key Components Glass/plastic barrels, plunger stoppers, tip caps [27] [26] Pen needles, containers, automated functions, electronics, on-body systems [25]
Core Testing Focus Container closure integrity, component strength, glide force [27] [26] Dose accuracy, functional performance, safety, usability [25]
Injection Force Context Measures Break-loose & extrusion force (BLEF) of the plunger in the syringe barrel [29] Considers force in system performance (e.g., injection time, automated functions) [25] [29]
Regulatory Status Recognized by FDA; conformity alone may not ensure device connectivity [24] Directly referenced in FDA guidance for injection devices [25]

Experimental Protocols and Testing Methodologies

Core Mechanical Tests for Prefilled Syringes (ISO 11040)

ISO 11040-4 specifies numerous mechanical tests to characterize syringe performance. Key tests related to injection force include:

  • Annex E: Glide Force Test: This test evaluates syringe lubrication by measuring the force required to move the plunger stopper down the barrel at a constant speed. It assesses both the initial break-loose force (the force to initiate movement from a stationary state) and the subsequent glide force (dynamic friction) [26]. Proper glide force is imperative for continuous drug delivery [26].
  • Annex C1: Flange Breakage Resistance: This test measures the force at which the round flange at the syringe base breaks. In autoinjectors, this flange bears the entire reaction force from device activation. The test is crucial for ensuring the syringe can withstand abrupt, high initial forces without failure [26] [30].
  • Break-Loose and Extrusion Force (BLEF) Testing: While not always explicitly named in the standard, BLEF tests are a common industry practice that aligns with its principles. A tensometer drives the plunger at a constant speed, measuring the varying force. The resulting force-distance chart provides data on break-loose force, extrusion force (dynamic friction plus drug formulation back-pressure), and can indicate expelled air bubbles [29].
Performance Verification for Injection Systems (ISO 11608)

ISO 11608-1 establishes requirements for verifying the overall performance of needle-based injection systems. Key methodologies include:

  • Dose Accuracy Testing: This is a critical performance requirement. It involves measuring the volume of liquid actually expelled by the device and comparing it to the intended dose. Automated test setups often integrate a precision balance to collect and weigh the expelled fluid, calculating the delivered volume with high accuracy [30].
  • Functional Stability and Shelf-Life Testing: The standard requires testing to simulate whole-life testing for reusable devices and to determine device shelf life. This involves assessing primary functions—those that allow the device to be used safely and effectively—after subjecting the device to accelerated aging conditions that simulate the effects of time [28]. A key concern is desiliconisation, where the silicone lubricant in a prefilled syringe degrades over time, increasing plunger-syringe friction and potentially leading to injection failure [29].
  • Human Factors and Simulated Use Studies: Beyond mechanical force measurement, the standard emphasizes the importance of human factors testing. This involves simulated use studies with human participants to assess perceived ease of injection, which research shows is not always directly correlated with measured injection forces [31].
Workflow for Injection Performance Characterization

The following diagram illustrates a generalized experimental workflow for characterizing injection device performance, integrating elements from both ISO standards.

G Start Start: Device/Component Selection A Define Test Objective Start->A B Component-Level Testing (ISO 11040) A->B C System-Level Testing (ISO 11608) A->C D Data Analysis & Modeling B->D BLEF Data C->D Injection Time Dose Accuracy E Performance Prediction & Spec Setting D->E

Diagram 1: Injection Performance Characterization Workflow

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 2: Essential Materials and Equipment for Injection Force Research

Item Function/Description Relevance to Standards
Universal Testing Machine A materials testing system (e.g., Instron, ZwickRoell) capable of tensile, compression, and torsion testing. Equipped with precision load cells and compliant software (e.g., Bluehill, testXpert) [27] [26]. Core equipment for performing BLEF, glide force, and breakage tests per ISO 11040 [27] [26].
Modular Syringe Fixtures Standard-compliant fixtures for holding syringes during testing (e.g., universal syringe holders, Luer cone alignment fixtures, flange test accessories) [27] [26]. Ensures correct, repeatable alignment for tests specified in ISO 11040-4 and -8, critical for reliable results [26].
Torsion Add-On An add-on to a universal testing machine that enables biaxial (axial + rotational) testing capabilities [27]. Required for evaluating torques, such as the unscrewing torque of rigid tip caps per Annex G.5 of ISO 11040 [27].
Precision Balance An integrated high-precision scale for weighing expelled liquids. Enables accurate dose delivery measurement as required by ISO 11040-8 and ISO 11608-1, removing manual steps and reducing error [30].
Aged/Shelf-Life Samples Syringes and devices subjected to accelerated aging conditions (e.g., elevated temperature) to simulate end-of-shelf-life performance [28] [29]. Critical for functional stability testing per ISO 11608-1 to predict performance degradation over time [28] [29].
Force Modeling Software Advanced software tools that translate basic BLEF test data into predictions of dynamic device performance and allowable force limits [29]. Helps bridge ISO 11040 component data with ISO 11608 system performance requirements, de-risking development [29].

Critical Considerations for Research and Development

The Connectivity Challenge: Beyond Standards Compliance

A critical finding from regulatory bodies is that conformity to ISO 11040-4 alone does not ensure a glass syringe will properly connect to connecting devices (e.g., needles, IV line luer connectors) without breakage or failure [24]. The FDA has reported adverse events, including syringe tips breaking upon injection and needles detaching, leading to delays in medication administration and potential patient harm [24]. This is because ISO 11040-4 lacks defined dimensions for key areas like the nozzle internal diameter and wall thickness, while the standard for connecting devices (ISO 594-2) has strict specifications [24]. Therefore, researchers must submit supplemental data on connectivity (interoperability) and consider design modifications, such as enlarging the nozzle's internal diameter, to ensure safe and effective use [24].

Correlating Measured Force with User Perception

Research indicates that a narrow focus on minimizing measured injection force may not fully capture the user experience. A 2018 comparative study found that while mechanical testing revealed significant differences in measured injection forces between three pen systems, these differences were not directly perceived by users in simulated injection studies [31]. This highlights a crucial distinction between instrument-measured force and human perception, underscoring the importance of integrating human factors testing and patient feedback early in the device development process, as emphasized in ISO 11608 [31] [28].

Advanced Modeling for Force and Performance Prediction

A novel approach to managing injection force involves advanced modeling software. Such tools, co-developed by industry and pharmaceutical partners, can use basic BLEF test data from ISO 11040 to predict a device's dynamic injection time and performance, accounting for factors like spring forces, fluid dynamics, and air bubble behavior [29]. This modeling is particularly valuable for forecasting performance at the end of shelf-life, where factors like desiliconisation increase plunger friction. By working backward from performance limits, researchers can set maximum allowable BLEF forces at time zero, de-risking development and reducing costly prototype iterations [29].

Techniques and Technologies for Accurate Injection Force Analysis

In the field of drug delivery systems research, the precise measurement of injection force is a critical parameter that directly impacts patient comfort, adherence, and ultimately, therapeutic outcomes. As pharmaceutical formulations become increasingly sophisticated—evolving from simple solutions to complex suspensions, microparticles, and high-viscosity biologics—the need for standardized, reliable test methods has never been more pressing. Injection force measurement spans the evaluation of simple pre-filled syringes to advanced self-injection devices, requiring specialized equipment and methodologies to generate reproducible, clinically relevant data. This comparative guide examines the two principal instrumental approaches for characterizing injectability: texture analyzers and universal testing machines. By objectively comparing their technical capabilities, applications, and limitations within the context of drug delivery research, this article provides scientists and development professionals with the foundational knowledge needed to select appropriate measurement technologies for their specific parenteral product development challenges.

The measurement of injection parameters extends beyond simple force quantification to encompass multiple performance characteristics. Syringeability refers to the ease with which a substance can be drawn into and expelled from a syringe, including factors such as ease of withdrawal, clogging tendencies, and accuracy of dose measurement [32] [5]. Injectability encompasses the performance during actual administration, including the pressure or force required for injection, evenness of flow, aspiration qualities, and freedom from clogging [16] [5]. Both parameters are profoundly influenced by formulation characteristics (viscosity, particle size and concentration, rheological properties) and device components (needle geometry, syringe barrel siliconization, plunger design) [16] [32] [33]. Establishing robust test methods for these parameters is essential throughout the product development lifecycle, from formulation screening to quality control of final products.

Texture Analyzers in Pharmaceutical Applications

Texture analyzers are benchtop instruments specifically engineered to measure mechanical properties that correlate with sensory characteristics, making them particularly suitable for evaluating parenteral delivery systems. Originally developed for food texture analysis, these instruments have been adapted with specialized fixtures and software to quantify key injection parameters. Modern texture analyzers, such as Stable Micro Systems' TA.XTplus or Mecmesin's OmniTest, function by applying controlled compressive or tensile forces to samples while precisely measuring displacement, thereby generating force-distance-time curves that characterize injection performance [32] [34] [35]. These systems typically offer force measurement capabilities ranging from less than 0.1 N to several hundred newtons, with displacement resolution as fine as 0.001 mm and speed control from 0.01 to 1200 mm/min [34].

For injection force measurement, texture analyzers are typically configured with specialized fixtures such as the Universal Syringe Rig (A/USR), which securely holds syringes of various sizes (typically 5-50 mm diameter) while the instrument's moving crosshead depresses the plunger [32] [35]. This setup allows researchers to quantify several critical parameters: the break-loose force (force required to initiate plunger movement), dynamic glide force (force required to sustain plunger movement), and maximum injection force (peak force during injection) [5] [33]. The accompanying software processes the resultant force-displacement curves to extract these parameters automatically, enabling high-throughput testing of multiple formulation-device combinations. This specialized approach makes texture analyzers particularly valuable for quantifying patient-centric aspects of injection, such as ease of use and perceived comfort during self-administration.

Universal Testing Machines: Expanded Capabilities

Universal testing machines (UTMs) represent a more flexible category of mechanical test instruments capable of performing both tension and compression tests across a much broader force range. While texture analyzers are essentially simplified UTMs optimized for specific applications, full-capability UTMs offer greater versatility in force capacity (from millinewtons to kilonewtons), higher accuracy specifications (±0.5% of reading or better), and more sophisticated materials testing capabilities [36] [34]. As noted in the search results, "Texture analyzers are essentially very simple universal testing machines" but UTMs are "much more flexible, able to test higher strengths while still having class-leading accuracy for more delicate material" [36]. This expanded capability makes UTMs suitable for evaluating not only the injection process itself but also complementary mechanical assessments such as container closure integrity, needle penetration force, and package functionality.

Modern UTMs feature modular designs with interchangeable load cells, a wide array of grips and fixtures, and sophisticated software that can be programmed to simulate various injection scenarios. For pharmaceutical applications, UTMs can be configured with syringe fixtures similar to those used on texture analyzers, but with the added capability of simultaneously measuring other mechanical properties relevant to device performance [36]. This includes testing the force required to remove needle shields (pull-off force), assessing plunger integrity under stress, and evaluating the mechanical robustness of auto-injector components. The principal advantage of UTMs lies in their versatility—a single instrument can typically perform injection force measurement, package integrity testing, and component validation studies, making them particularly valuable for resource-limited laboratories requiring broad mechanical testing capability beyond just injection characterization.

Table 1: Technical Comparison Between Texture Analyzers and Universal Testing Machines

Parameter Texture Analyzer Universal Testing Machine
Primary Application Focus Pharmaceutical syringeability/injectability, cosmetic applications, food texture Broad materials testing, mechanical properties, structural components
Typical Force Range 0.1 N to 500 N (specialized units to 2500 N) [34] <0.001 N to >50 kN (varies by model) [36]
Displacement Resolution 0.001 mm [34] Varies, typically 0.0001 mm to 0.001 mm
Speed Control Range 0.01 to 1200 mm/min [34] 0.001 to 2000+ mm/min
Standard Compliance Industry-specific methods, often based on sensory correlation ASTM, ISO, DIN standards for materials testing
Typical Syringe Fixtures Universal Syringe Rig, specialized disposable syringe holders [32] [35] Custom fixtures, often manufacturer-specific
Data Output Force-time-distance curves with specialized parameters (break-loose, glide force) [32] Stress-strain curves, fundamental material properties

Experimental Protocols for Injection Force Assessment

Standardized Methodology for Injectability Testing

Comprehensive injectability assessment requires carefully controlled experimental protocols that simulate real-world usage conditions while generating reproducible, quantitative data. The following methodology, synthesized from multiple research studies, provides a robust framework for evaluating injection performance using either texture analyzers or universal testing machines:

  • Sample Preparation: Prefilled syringes should be conditioned at the recommended storage temperature (typically 20-25°C) for at least 24 hours prior to testing, as temperature significantly affects viscosity and consequently injection force [32] [5]. For suspension formulations, homogeneity must be ensured through appropriate mixing protocols immediately before testing to prevent settling during measurement [16].

  • Instrument Configuration: The testing instrument should be calibrated according to manufacturer specifications, with an appropriate load cell selected for the expected force range (typically 5-100 N for most subcutaneous injections) [5] [34]. The syringe is securely positioned in the fixture (e.g., Universal Syringe Rig) with the needle oriented downward, and the plunger is aligned with the instrument's compression probe [32] [35].

  • Test Parameters: A crosshead speed of 1 mm/s is widely used as representative of manual injection by patients, though auto-injector simulations may require higher speeds (up to 300 mm/min or more) [5] [33]. The test should continue until the plunger reaches its end position or a predetermined displacement corresponding to the intended dose volume.

  • Data Collection and Analysis: Force-displacement data should be collected at a minimum frequency of 50 Hz to capture transient force variations [5]. From the resulting curve, three key parameters should be extracted: (1) Break-loose force - the initial peak force required to initiate plunger movement; (2) Maximum force (Fmax) - the highest force recorded during injection; and (3) Dynamic glide force - the average force during sustained plunger movement [5] [33]. These values are typically normalized by dividing by the cross-sectional area of the plunger and expressed in pressure units (mPa) for comparative analysis [5].

Advanced Methodologies for Specialized Formulations

For complex drug delivery systems such as microparticle suspensions and high-viscosity biologics, additional methodological considerations are necessary to generate clinically relevant data. Research by Sun et al. demonstrated that comprehensive injectability evaluation should include both injection force and discharge rate measurements, particularly for microparticle delivery systems where particle retention in the syringe or needle can significantly impact delivered dose [16]. Their methodology involved testing multiple parameters including particle size (with larger particles >50μm dramatically increasing injection force), suspension concentration (optimal range 120-240 mg/mL), vehicle viscosity (60 cP at 20°C provided good injectability), and needle geometry (23-gauge needles offered the best balance between patient comfort and injectability for microparticles) [16].

When evaluating high-viscosity formulations (>30 cP), such as concentrated monoclonal antibodies, the methodology should account for their non-Newtonian rheological behavior. Studies have shown that shear-thinning formulations may actually demonstrate decreased injection forces at higher injection rates, contrary to intuitive expectations [33] [8]. Additionally, specialized needle designs including tapered needles (e.g., 29G TNN) and thin-wall configurations (e.g., 27G TW) can significantly reduce injection forces for viscous solutions, with mathematical modeling supporting their performance advantages [8]. For these complex systems, a Design of Experiment (DOE) approach is recommended to efficiently evaluate multiple interacting variables and identify optimal formulation-device combinations [16].

Comparative Performance Data and Applications

Quantitative Performance Comparison

Direct comparison studies provide valuable insights into the performance characteristics of different injection systems and the equipment used to evaluate them. Donsmark et al. conducted a systematic comparison of insulin pen injection forces, finding that the NovoPen 4 required significantly lower injection force (9.14 ± 0.87 N with 30-gauge needles) compared to the NovoPen 3 (18.36 ± 1.06 N with the same needles)—a reduction of approximately 50% [37]. This dramatic improvement demonstrates how device optimization can directly impact user experience, particularly for patients with manual dexterity challenges. After simulated lifetime testing (5,475 injections), the NovoPen 4 maintained its performance advantage, with injection forces of 10.93 ± 0.77 N compared to 18.54 ± 0.94 N for the NovoPen 3 [37].

Similar comparative studies have quantified the impact of needle geometry on injection performance. Research on prefilled syringes equipped with tapered needles (29G TNN) demonstrated injection forces lower than standard 29G thin-wall needles and similar to 27G thin-wall needles for Newtonian solutions, with even greater advantages for shear-thinning formulations [8]. Complementary research on high-viscosity formulations (30-50 cP) showed that 8mm special thin-wall needles could reduce break-loose and glide forces by approximately 25% compared to standard ½" thin-wall needles [33]. These quantitative comparisons highlight the critical importance of both device design and formulation characteristics in determining injection performance.

Table 2: Injection Force Comparison Across Different Delivery Systems

Delivery System Formulation Type Needle Configuration Injection Force (Mean ± SD) Reference
NovoPen 3 Insulin solution 30-gauge 18.36 ± 1.06 N [37]
NovoPen 4 Insulin solution 30-gauge 9.14 ± 0.87 N [37]
Prefilled syringe Newtonian solution 29G tapered needle Similar to 27G TW [8]
Prefilled syringe Non-Newtonian solution 29G tapered needle Lower than 27G TW [8]
Prefilled syringe High-viscosity (30-50 cP) 8mm STW 25% reduction vs. ½" TW [33]
Manual acceptability threshold Various Various Fmax < 125 mPa (smooth) [5]
Manual acceptability threshold Various Various Fmax > 250 mPa (impractical) [5]

Correlation Between Measured Forces and User Perception

An essential consideration in injection force measurement is the relationship between instrument-measured parameters and actual user experience. Schneider et al. conducted a comparative study contrasting measured injection force with users' perceived ease of injection, revealing that although mechanical testing showed significant differences between three pen systems' injection forces, "these differences were not directly perceived by users in simulated injection studies" [31]. This finding suggests that users' perceived ease of injection may be less sensitive to measured injection forces than prior research assumed, highlighting the importance of complementing instrumental measurements with human factors studies during device development.

Research by Cilurzo et al. established a scoring system to correlate measured injection forces with user assessments, proposing specific thresholds for manual injectability: Fmax up to 125 mPa was associated with smooth injection, 125-160 mPa with feasible but somewhat difficult injection, 160-250 mPa with very difficult injection, and above 250 mPa with practically impossible injection [5]. This correlation between quantitative force measurements and qualitative user experience provides valuable guidance for establishing acceptability criteria during product development, helping to ensure that optimized formulations and devices will be acceptable to end users in real-world settings.

Essential Research Reagents and Materials

Successful injection force measurement requires not only appropriate instrumentation but also careful selection of complementary materials and reagents that can significantly impact test results. The following table summarizes key components essential for comprehensive injectability assessment:

Table 3: Essential Research Materials for Injection Force Testing

Material/Component Function in Testing Considerations and Impact
Prefilled syringes Primary test article representing final product configuration Barrel siliconization level affects break-loose and glide forces [33]
Needle arrays Evaluating impact of needle geometry on injectability Gauge, length, wall thickness, and taper design significantly affect injection force [16] [33] [8]
Model formulations Simulating drug products with specific rheological properties Viscosity, particle size/concentration, and Newtonian/non-Newtonian behavior affect forces [16] [5]
Standard viscosity fluids Instrument qualification and method validation Certified viscosity standards ensure measurement accuracy across tests
Syringe fixtures Secure positioning of syringes during testing Universal designs accommodate various syringe sizes (5-50mm diameter) [32] [35]
Temperature control system Maintaining consistent test conditions Temperature affects viscosity; typical control at 20±1°C [16] [5]

The systematic comparison of texture analyzers and universal testing machines for injection force measurement reveals distinct but complementary roles in drug delivery research. Texture analyzers offer application-focused testing with specialized fixtures and methodologies specifically designed for pharmaceutical injectability assessment, providing readily interpretable data correlated with user experience. Universal testing machines deliver broader mechanical testing capabilities with higher force capacity and accuracy, suitable for comprehensive device characterization beyond just injection performance. The selection between these platforms should be guided by specific research objectives, with texture analyzers providing optimized workflow for formulation screening and device comparison, and UTMs offering greater versatility for fundamental research and complete device validation.

Future developments in injection force measurement will likely focus on increasing physiological relevance through more sophisticated test methodologies that better simulate subcutaneous tissue resistance [5], enhanced correlation between instrumental measurements and patient-reported outcomes [31], and standardized approaches for evaluating increasingly complex drug delivery systems such as microparticles and high-concentration biologics [16]. Additionally, the growing importance of combination products (drug-device combinations) necessitates more integrated testing approaches that evaluate both mechanical performance and biological efficacy. As pharmaceutical formulations continue to evolve toward more patient-centric delivery systems, robust, standardized test methods will remain essential for ensuring that therapeutic advances translate into improved user experiences and treatment outcomes.

Advanced Sensor Kits and Real-Time Data Acquisition Systems

In the specialized field of injection force measurement for drug delivery systems, the integrity of experimental data is paramount. Advanced sensor kits and real-time Data Acquisition (DAQ) systems provide the technological foundation for capturing precise, high-fidelity measurements critical for characterizing injectability. These systems convert physical phenomena, such as the force required to depress a syringe plunger, into digital data that researchers can analyze to optimize formulation viscosity, needle geometry, and injection parameters [38]. The selection of an appropriate DAQ system directly influences the reliability, accuracy, and actionability of data in pharmaceutical development.

This guide objectively compares the performance of standalone data loggers and real-time DAQ systems, contextualizing their capabilities within the rigorous demands of injection force research. For drug development professionals, the choice between these technologies impacts everything from protocol design to the validity of regulatory submissions. The following sections provide a detailed comparison based on technical specifications, experimental data, and practical implementation protocols to inform strategic equipment selection.

System Comparison: Data Loggers vs. Real-Time DAQ Systems

Data acquisition solutions exist on a spectrum from basic data loggers to sophisticated real-time DAQ systems. Understanding their fundamental differences is the first step in selecting the right tool for a research environment.

Data Loggers are typically self-contained, battery-powered devices designed for long-term, low-frequency monitoring of environmental parameters like temperature or humidity. They record data at predetermined intervals to internal memory or removable storage, functioning primarily as passive recording devices with limited real-time feedback capabilities [39] [40]. Their design prioritizes energy efficiency and simplicity over speed and real-time processing.

Real-Time DAQ Systems are combinations of hardware and software designed for high-speed, multi-channel measurement. They capture data from various sensors and instruments, converting it into a format suitable for immediate analysis and interpretation [38]. Unlike loggers, they facilitate active, real-time monitoring and can trigger instant alerts or control outputs when measured parameters deviate from setpoints, which is crucial for dynamic testing environments [39] [40].

The architectural differences between these systems are summarized in the diagram below.

ArchitectureComparison cluster_Logger Data Logger Architecture cluster_RealTimeDAQ Real-Time DAQ System Architecture LoggerSensors Sensors (Temp, Humidity) LoggerUnit Data Logger Unit (Low Power, Internal Memory) LoggerSensors->LoggerUnit Low-Speed Data LoggerStorage Internal Memory or SD Card LoggerUnit->LoggerStorage Periodic Storage LoggerPC PC for Data Retrieval LoggerStorage->LoggerPC Manual Download DAQSensors Advanced Sensor Kit (Force, Pressure, Vibration) DAQHardware DAQ Hardware (High-Speed, Multi-Channel) DAQSensors->DAQHardware High-Speed Data DAQSoftware Real-Time Processing Software DAQHardware->DAQSoftware Real-Time Stream DAQStorage Live Data Stream & High-Capacity Storage DAQSoftware->DAQStorage Continuous Recording DAQAlerts Instant Alerts & Control Outputs DAQSoftware->DAQAlerts Immediate Feedback

Quantitative Performance Comparison

The architectural differences translate into distinct performance characteristics, which are critical for application-specific selection. The table below summarizes the key technical differences between these systems, with data compiled from industry sources [39] [40].

Table 1: Technical Performance Comparison: Data Loggers vs. Real-Time DAQ Systems

Feature Data Loggers Real-Time DAQ Systems
Typical Sampling Rate Low (1 to 100 samples/second) [40] High (100 kS/s to 1 MS/s and beyond) [41] [40]
Data Storage Internal memory, USB drives, or SD cards [40] High-capacity Solid-State Drives (SSDs) [40]
Real-Time Monitoring & Control Limited or none; post-process analysis [39] [40] Yes; instant alerts and control outputs [39] [40]
Power Source Battery-powered for energy efficiency [39] [40] External AC/DC power or rechargeable battery packs [40]
Typical Application Long-term environmental monitoring (temperature, humidity) [40] Dynamic testing and measurement (injection force, vibration) [41] [38]
Critical Advantage Portability and long-term deployment High-speed data integrity and proactive intervention

For injection force measurement, which requires capturing rapid changes in pressure and force, the high sampling rate and real-time capabilities of DAQ systems are indispensable. A system with a sampling rate of at least 10 times faster than the fastest signal needing capture is recommended to faithfully reproduce the signal's character [41].

The Scientist's Toolkit: Essential Research Reagent Solutions

The following table details key components and reagents essential for conducting robust injection force experiments, as identified in the literature [5] [16] [42].

Table 2: Essential Materials for Injection Force Measurement Research

Item Function/Description Experimental Role
Texture Analyzer / Universal Testing Machine Software-controlled instrument that measures compression and tension forces with high accuracy. The primary instrument for quantifying plunger-stopper breakloose force, maximum force (Fmax), and dynamic glide force during syringe injection [5].
Pre-filled Syringes (Luer Lock) Syringes with a locking connection for secure needle attachment, ensuring no disconnection under high pressure. The standard container-closure system for the injectable formulation under test; eliminates variables from manual filling [5] [16].
Hypodermic Needles (Various Gauges & Lengths) Stainless-steel needles varying in inner diameter (gauge) and length (e.g., 21G-27G, 16-40 mm). To study the critical impact of needle geometry on injection force. Smaller gauges (larger diameters) generally reduce force [5] [16].
Model Formulations (Varying Viscosity) A range of fluids, from low-viscosity solutions to high-viscosity lipid-based systems or suspensions. To establish the correlation between formulation viscosity and the force required for injection [5] [42].
Ex Vivo Tissue Model Excised subcutaneous tissue (e.g., from human donors or animal models like minipigs). Provides a biologically relevant medium to measure tissue back-pressure, a significant component of in vivo injection force [5] [42].

Experimental Protocols for Injectability Assessment

A standardized experimental protocol is vital for generating reproducible and comparable data on injection force. The following workflow, derived from published methodologies, outlines a comprehensive approach for evaluating a needle-syringe-formulation system [5].

ExperimentalWorkflow cluster_Step1 cluster_Step5 cluster_Step6 Step1 1. System Setup Step2 2. Sensor Calibration Step1->Step2 Syringe Fill Syringe with Test Formulation Step1->Syringe Step3 3. In-Air Force Measurement Step2->Step3 Step4 4. Ex Vivo Force Measurement Step3->Step4 Step5 5. Data Acquisition Step4->Step5 Step6 6. Data Analysis & Scoring Step5->Step6 Params Record Force (N) vs. Plunger Displacement (mm) Step5->Params Fmax Extract Fmax (Maximum Force) Step6->Fmax Needle Attach Specified Needle Gauge Syringe->Needle Mount Mount in Texture Analyzer Needle->Mount Score Apply Clinical Injectability Score Fmax->Score

Detailed Methodology:

  • System Setup: A Luer Lock glass syringe is filled with a precise volume (e.g., 1 mL) of the test formulation. A needle of a specific gauge and length is securely attached. The syringe is then mounted in the texture analyzer's holder, positioning the plunger end in contact with a calibrated load cell (e.g., 5 N capacity) [5].
  • Sensor Calibration: The texture analyzer and load cell must be calibrated using standard weights traceable to national standards prior to measurement to ensure data accuracy.
  • In-Air Force Measurement (Baseline): The measurement is initiated with the texture analyzer's crosshead moving at a constant speed (e.g., 1 mm/s, representative of manual injection). The force required to displace the plunger is recorded as a function of plunger displacement. This test in air provides a baseline force, primarily accounting for the friction between the plunger and syringe barrel [5].
  • Ex Vivo Force Measurement (Tissue Back-Pressure): The needle is inserted into an ex vivo subcutaneous tissue model (e.g., human abdominal skin from a donor). The force measurement is repeated under identical instrument settings. The force profile in this case includes both the device friction (from Step 3) and the resistance from the tissue [5] [42].
  • Data Acquisition: A real-time DAQ system is crucial for capturing the force-displacement data at a high sampling rate (e.g., 50 Hz). This ensures that transient force peaks are accurately recorded without aliasing. The data is streamed directly to storage for post-processing [5].
  • Data Analysis & Scoring: From the force-displacement plot, key parameters are extracted:
    • Plunger-stopper breakloose force: The force required to initiate plunger movement.
    • Maximum force (Fmax): The highest force recorded during the injection.
    • Dynamic glide force: The force required to sustain plunger movement [5].

The extracted Fmax value is then compared against established clinical injectability thresholds, as shown in the table below.

Table 3: Clinical Injectability Scoring Based on Maximum Force (Fmax)

Maximum Force (Fmax) Injectability Score Clinical Interpretation
Up to 125 mPa 4 Injection proceeds smoothly [5].
125 - 160 mPa 3 Feasible, though with some difficulty [5].
160 - 250 mPa 2 Injection is very difficult [5].
> 250 mPa 1 Injection is practically impossible [5].

Performance Data and Experimental Evidence

Empirical data is essential for understanding how formulation and device parameters interact to affect injectability. The following table synthesizes key findings from controlled studies.

Table 4: Impact of Formulation and Device Parameters on Injection Force

Parameter Experimental Finding Research Context
Formulation Viscosity Injection force increases linearly with viscosity. For example, force increased from ~1 N (1 mPa·s) to ~5 N (20 mPa·s) at an injection rate of 0.2 mL/s [42]. In vivo injection study in minipigs.
Needle Gauge (Diameter) Needle gauge has the "greatest influence on injectability." Larger gauges (smaller inner diameters) result in significantly higher injection forces and potential clogging [16]. In vitro study of microparticle suspension injectability.
Injection Speed/Rate Higher injection rates (e.g., 0.2 mL/s vs. 0.025 mL/s) led to a marked increase in both the average and variability of injection force, especially for more viscous formulations [42]. In vivo injection study in minipigs.
Particle Size & Shape Larger particle sizes and irregular shapes (e.g., mesoporous silica vs. spherical glass beads) led to poorer injectability, including higher injection force and lower discharge rates [16]. In vitro force measurement and sieve test for microparticles.
The Role of Software and System Integration

The software platform controlling the DAQ system is a critical, often overlooked, component. It governs data acquisition, instrument control, and real-time analysis. A performance comparison of programming languages used for instrument automation revealed significant differences in execution time for data acquisition and real-time control tasks. In one study, LabVIEW completed a runtime analysis task fastest (365.69 s), while MATLAB performed best (640.33 s) when the experiment included integrated data processing [43]. This highlights that the optimal software environment can depend on the specific balance of control speed and processing complexity required by the experiment.

In the field of drug delivery, the mechanical force required to administer a therapeutic agent is a critical parameter that directly influences device usability, patient comfort, and therapeutic efficacy. Injection force measurement provides essential data for optimizing device design and formulation, particularly as the industry shifts toward patient self-administration of high-viscosity biologic drugs [44]. The growing prevalence of chronic diseases requiring subcutaneous injection of concentrated protein-based solutions has intensified the need for precise characterization of injection dynamics [44]. This comparative guide objectively evaluates the performance of various drug delivery systems through the lens of injection force measurement, providing researchers with methodological frameworks and quantitative data to inform device selection and development.

Comparative Analysis of Drug Delivery Systems

Table 1: Performance Comparison of Injectable Drug Delivery Systems

Delivery System Typical Injection Force Range Optimal Viscosity Range Key Advantages Primary Limitations Clinical Applications
Prefilled Syringes 13-32 N (glide force for 1 mL) [44] Low to moderate (tested with 20 cP solution) [44] Dosing accuracy, convenience, reduced medication errors [44] High injection forces with viscous formulations [44] Vaccines, biologics, hormones [45]
Autoinjectors Varies with mechanism Varies with mechanism Ease of use for self-administration [46] Limited volume capacity, potential for high pain at high forces Rheumatoid arthritis, multiple sclerosis, anaphylaxis [47] [46]
Gas-Powered Injectors Significantly reduced vs. mechanical springs [47] High viscosity formulations [47] Handles high viscosity/volume formulations, reduced user force [47] More complex mechanism, potential for higher cost Monoclonal antibodies, other biologics [47]
Wearable/On-Body Injectors Minimal patient-applied force Medium to high volume (≥2 mL) [47] Slow injection reduces pain, enables large volume delivery [47] Larger form factor, higher cost per device Chronic disease management (e.g., pegfilgrastim) [47]
Self-Assembling Depots Not quantified in available studies Hydrophobic drug crystals [48] Long-acting (months to years), small needle gauge [48] Surgical removal may be required to halt treatment [48] Contraception, HIV, tuberculosis [48]

Table 2: Technical Specifications and Component Impact on Injectability

System Component Design Variation Impact on Injection Force & Performance Experimental Findings
Needle Transition from 29-gauge to 27-gauge 59% reduction in glide force (32 N → 13 N) [44] Enhanced injectability for high-viscosity formulations [44]
Plunger Stopper Reduced contact length with barrel Decreased friction force [44] Critical factor in injectability optimization [44]
Syringe Barrel Internal cross-sectional area Influences pressure and force requirements [44] Requires optimization based on formulation properties [44]
Lubrication Silicone oil coating techniques Significant impact on barrel friction [44] Diving-nozzle vs. fixed-nozzle processes affect performance [44]
Power Mechanism Gas canister vs. mechanical spring Higher energy density for challenging formulations [47] Enables delivery of high-viscosity monoclonal antibodies [47]
Formulation Adjuvants (e.g., hyaluronidase) Reduced injection site pain [47] Facilitates larger volume delivery (e.g., VYVGART Hytrulo) [47]

Experimental Protocols for Injection Force Measurement

Prefilled Syringe Optimization Methodology

The investigation of critical prefilled syringe (PFS) design elements follows a systematic protocol to quantify their impact on injection force [44]. The methodology encompasses both technical measurements and human factors assessment:

  • Material Preparation: Aqueous solutions of polyethylene glycol 6000 (PEG 6000) at varying concentrations are prepared and sterilized through 0.22 µm membrane filtration to create test media with controlled viscosity properties [44].

  • Component Sourcing: Pre-fillable syringes are sourced from multiple vendors including SCHOTT Pharma, Becton, Dickinson and Company (BD), and Ompi to ensure representative sampling of commercially available components [44].

  • Force Measurement Apparatus: A universal testing machine equipped with appropriate force transducers is used to measure glide force during simulated injection. The machine is programmed to administer 1 mL of a 20-centipoise viscous fluid over a 10-second injection duration to standardize measurements [44].

  • Barrel Friction Assessment: Prefilled syringes with different silicone spray processes (diving-nozzle and fixed-nozzle) are compared to assess siliconization effects on barrel friction. Three different bromobutyl plunger stoppers from various vendors are evaluated in this configuration [44].

  • Human Factors Integration: A simulated human factors study with a diverse cohort (n=12) evaluates the usability of optimized devices. The correlation between reduced glide force and user perception/usability is quantified through standardized assessment instruments [44].

Gas-Powered Injector Performance Assessment

The evaluation of gas-powered injection systems for high-viscosity biologics involves distinct methodological considerations [47]:

  • Energy Density Quantification: Comparative analysis of energy delivery between traditional mechanical springs and compressed/liquefied gas canisters, measuring the force profiles across the injection cycle.

  • Formulation Compatibility Testing: Assessment of device performance with high-viscosity monoclonal antibody formulations, measuring complete delivery success rates and residual volume.

  • Use Error Analysis: Human factors testing with target patient populations to evaluate handling, administration success, and subjective comfort compared to traditional delivery systems.

Visualization of System Relationships and Workflows

Injection Force Optimization Pathways

InjectionForce Start Drug Formulation Requirements DesignFactors Device Design Factors Start->DesignFactors Needle Needle Gauge & Geometry DesignFactors->Needle Plunger Plunger Stopper Design DesignFactors->Plunger Lubrication Barrel Lubrication System DesignFactors->Lubrication ForceMeasurement Injection Force Measurement Needle->ForceMeasurement Plunger->ForceMeasurement Lubrication->ForceMeasurement HumanFactors Human Factors Assessment ForceMeasurement->HumanFactors Optimization Optimized Injection System HumanFactors->Optimization

Drug Delivery System Selection Logic

SystemSelection Start Drug Delivery Requirements Viscosity High Viscosity Formulation? Start->Viscosity Volume Volume > 2 mL Required? Viscosity->Volume Yes Prefilled Prefilled Syringes Viscosity->Prefilled No Duration Long-Acting (Months)? Volume->Duration Yes GasPowered Gas-Powered Injectors Volume->GasPowered No Wearable Wearable/On-Body Injectors Duration->Wearable No SelfAssembling Self-Assembling Depots Duration->SelfAssembling Yes SelfAdmin Patient Self-Administration? SelfAdmin->GasPowered No SelfAdmin->Wearable Yes GasPowered->SelfAdmin

Research Reagent Solutions for Injection Force Studies

Table 3: Essential Materials and Reagents for Injection Force Research

Research Solution Function/Application Key Characteristics Representative Examples
PEG 6000 Solutions Viscosity standard for simulating drug formulations [44] Chemically pure grade, pH 6.0, sterilized by 0.22 µm filtration [44] Sinopharm Chemical Reagent Co., Ltd. [44]
Pre-fillable Syringes Primary container for injectability studies [44] Various vendors and specifications for comparative testing SCHOTT Pharma, BD, Ompi [44]
Bromobutyl Plunger Stoppers Closure system affecting friction forces [44] Various vendors/designs for performance comparison Multiple commercial sources [44]
Universal Testing Machine Quantification of glide force and injection dynamics [44] Programmable injection speed and volume parameters Industry-standard equipment [44]
Human Factors Assessment Tools Usability evaluation of optimized devices [44] Standardized instruments for subjective perception metrics Diverse cohort studies (n=12) [44]
VapourSoft Technology Compact energy source for injection devices [46] Enables smaller device designs vs. traditional springs Bespak's Syrina autoinjector range [46]

In the development of drug delivery systems, a significant challenge persists: accurately predicting how an injection device will perform throughout its entire shelf life. The nightmare scenario for device engineers is investing years in design, tooling, and verification testing, only to have the device fail its performance requirements at the end of its shelf life due to unanticipated changes in injection force dynamics [29]. Traditionally, device development has relied heavily on physical prototyping and testing—an iterative process that is both time-consuming and costly. However, a transformative approach has emerged that bridges mechanical testing with statistical forecasting: the application of Monte Carlo simulations to Break-Loose and Extrusion Force (BLEF) data. This methodology enables engineers to translate basic syringe test data into accurate predictions of injection device performance, accounting for normal manufacturing variations and age-related degradation [29]. For researchers and drug development professionals, this approach represents a paradigm shift from reactive testing to proactive performance forecasting, potentially accelerating time to market while enhancing device reliability.

Understanding Core Data: What is BLEF Testing?

Break-Loose and Extrusion Force (BLEF) testing is a fundamental characterization method for prefilled syringes and injection systems. In a standard BLEF test, a tensometer drives a plunger at a constant speed while measuring the varying force required as the plunger moves down the syringe barrel [29]. The resulting force-distance chart provides three critical parameters:

  • Break-Loose Force (PBF): The initial force required to overcome the static friction between the stationary plunger and the syringe barrel.
  • Extrusion Force: The force required to maintain plunger movement, comprising both the dynamic friction between the plunger and syringe wall and the fluid dynamic resistance of the formulation being expelled.
  • Air Bubble Signature: A small force dip indicating the expulsion of an air bubble after the primary drug delivery [29].

While BLEF testing is invaluable for characterizing relationships between forces and parameters such as plunger speed, syringe dimensions, and fluid properties, it has a fundamental limitation. The constant-speed nature of BLEF testing does not accurately reflect the dynamic injection behavior of spring-driven autoinjectors, where plunger speed varies throughout the injection as spring force decreases [29]. This discrepancy between standardized testing and real-world performance creates uncertainty in device development, particularly when accounting for how performance characteristics change over the device's shelf life.

The Predictive Framework: From BLEF Data to Performance Forecasting

The Modeling Approach: A Time-Stepped Simulation

To bridge the gap between BLEF data and device performance prediction, Sanner Group's Design Centre of Excellence (Springboard), in collaboration with Pfizer's Devices Centre of Excellence, co-developed advanced modeling software that employs a sophisticated time-stepped simulation approach [29]. This method breaks down the injection process into discrete, calculable steps:

  • Initial State Calculation: Each simulation loop begins with a known plunger position, which determines the current spring length and corresponding spring force.
  • Force-Equilibrium Assumption: The model assumes the spring force approximately equals the current extrusion force.
  • Velocity and Pressure Calculation: Using relationships derived from the input BLEF data, the extrusion force is used to calculate the current plunger speed and internal syringe pressure.
  • Fluid Dynamics Application: The Hagen-Poiseuille equation is applied across the needle to relate pressure to the velocity of fluid being ejected.
  • Volume Accounting: The model calculates plunger movement based on the reduction in injection volume while simultaneously accounting for changes in air bubble volume due to pressure fluctuations [29].

This cyclical process repeats until the full nominal volume has been delivered, with the accumulated time providing the total injection time prediction.

Incorporating Variability: The Monte Carlo Method

A critical innovation in this approach is the integration of the Monte Carlo method to account for real-world variability. The software randomly samples from user-specified tolerances on input parameters and the natural variance observed in empirical BLEF data [29]. By running thousands of simulations, each with slightly different parameter values sampled from their respective probability distributions, the model generates a comprehensive distribution of possible injection times rather than a single point estimate. This allows device developers to understand not just typical performance, but the full range of possible outcomes and their respective probabilities—essential information for setting robust performance specifications and assessing failure risks.

G cluster_loop Time-Stepped Simulation Loop BLEF Test Data BLEF Test Data Monte Carlo Simulation Monte Carlo Simulation BLEF Test Data->Monte Carlo Simulation Time-Stepped Model Time-Stepped Model Monte Carlo Simulation->Time-Stepped Model Input Parameter Distributions Input Parameter Distributions Input Parameter Distributions->Monte Carlo Simulation Performance Distribution Performance Distribution Time-Stepped Model->Performance Distribution Plunger Position Plunger Position Time-Stepped Model->Plunger Position Spring Force Spring Force Plunger Position->Spring Force Extrusion Force Extrusion Force Spring Force->Extrusion Force Plunger Speed Plunger Speed Extrusion Force->Plunger Speed Fluid Velocity Fluid Velocity Plunger Speed->Fluid Velocity Volume Change Volume Change Fluid Velocity->Volume Change Volume Change->Plunger Position

Accounting for Device Ageing

Performance degradation over a device's shelf life presents a particular challenge in device development. Desiliconisation of the syringe barrel—the gradual reduction of silicone oil lubrication over time—is a primary factor increasing plunger-syringe friction and consequently injection force [29]. The modeling approach addresses this by using newly siliconized and fully desiliconized syringes as best-case and worst-case boundary conditions for plunger-syringe friction. The software can establish ageing trends using a limited number of single-speed BLEF tests on aged syringes, then model the effect by increasing theoretical BLEF values until devices stall or breach injection time limits [29]. This capability enables reverse calculation—working backwards from end-of-shelf-life performance requirements to determine maximum allowable BLEF results at time zero, providing clear specifications for component manufacturers.

Experimental Protocols and Validation

BLEF Testing Methodology

Standardized BLEF testing follows precise experimental protocols to ensure reproducible and meaningful data. The ISO 11040-8 standard mandates that tests use the complete, final system "as intended for use" and requires designers to consider how forces vary with ageing and environmental factors [29]. Typical experimental setups include:

  • Equipment: Compression testing systems such as the Instron 5940 Series, which can measure forces with high precision across a range of applications up to 2 kN [7].
  • Test Configuration: Syringes are mounted in the testing system, and plungers are driven at constant speeds (commonly 100 mm/min) while force and displacement data are recorded [7].
  • Environmental Controls: Testing should be conducted under controlled temperature and humidity conditions, as these factors can significantly affect fluid viscosity and friction characteristics.
  • Sample Size: Typically, multiple replicates (n≥3) of each syringe-needle combination are tested to account for normal manufacturing variations [7].

Performance Validation Studies

Comprehensive validation studies have demonstrated the critical relationship between device configuration and injection performance. One extensive study evaluated multiple autoinjector and syringe-needle combinations across viscosity levels ranging from 11 cP to 70 cP, with 20 replicates per configuration to ensure statistical robustness [49]. The study measured injection time from activation to full dose expulsion using high-speed cameras tracking plunger movement at 50 frames per second [49]. Results demonstrated that higher viscosities significantly increase injection times, with measurements ranging from 3.63 seconds at 11 cP (27G UTW 8 mm needle) to 37.45 seconds at 70 cP (27G STW 12.7 mm needle) [49]. These empirical findings provide valuable validation data for predictive models, confirming the substantial impact of both needle geometry and fluid properties on device performance.

Comparative Performance Data

The table below synthesizes experimental data from autoinjector performance studies, illustrating how different syringe-needle configurations affect injection times across various viscosity levels [49].

Table 1: Injection Time Comparison Across Syringe-Needle Configurations and Viscosities

Needle Configuration 11 cP (seconds) 23 cP (seconds) 36 cP (seconds) 53 cP (seconds) 70 cP (seconds)
27G UTW 8 mm 3.63 7.30 11.37 17.23 23.33
27G STW 8 mm 5.10 10.05 15.87 23.87 32.47
27G STW 12.7 mm 6.08 12.57 20.13 30.83 37.45
29G ETW 8 mm 8.13 16.63 27.17 N/A N/A

The performance differentials highlighted in Table 1 demonstrate several key principles in device performance. First, ultra-thin wall (UTW) needle designs consistently outperform other configurations across all viscosity levels due to their larger internal diameters, which reduce fluid resistance according to the Hagen-Poiseuille equation [49]. Second, needle length has a measurable but secondary effect compared to internal diameter, with shorter needles (8 mm) providing better performance than longer needles (12.7 mm) across comparable wall thicknesses. Third, the performance gap between configurations widens as viscosity increases, highlighting the particular importance of needle optimization for high-viscosity formulations.

Table 2: Essential Research Tools for BLEF-Based Predictive Modeling

Tool Category Specific Examples Function in Predictive Modeling
Force Measurement Systems Instron 5940 Series [7] Precisely measures break-loose and extrusion forces during BLEF testing under controlled conditions.
Modeling Software Sanner Group/Pfizer co-developed software [29] Implements time-stepped algorithms and Monte Carlo simulations to translate BLEF data into device performance predictions.
High-Speed Imaging 50 fps camera systems [49] Tracks plunger movement and validates injection time predictions in experimental studies.
Rheological Instruments Viscometers [16] Characterizes formulation viscosity, a critical input parameter for accurate force modeling.
Statistical Analysis Tools Monte Carlo simulation packages [29] Accounts for parameter variability and generates performance distributions from deterministic inputs.

The integration of BLEF data with Monte Carlo simulations represents a significant advancement in drug delivery device development. This approach transforms the traditional build-and-test paradigm into a more efficient model-specify-verify workflow, enabling developers to replace physical prototyping with mathematical modeling [29]. For researchers and drug development professionals, these predictive capabilities offer multiple advantages: reducing development costs by identifying potential failures early, accelerating time to market through reduced prototyping cycles, and enhancing device reliability by accounting for performance degradation over shelf life. As drug formulations continue to evolve toward higher viscosities and more challenging delivery profiles, these predictive modeling approaches will become increasingly essential for developing devices that balance performance requirements with user experience and manufacturing practicality.

Solving Injectability Challenges in Complex Formulations and Devices

Overcoming High-Viscosity Challenges with Novel Device Technologies

The rapid growth of biologic therapies, particularly monoclonal antibodies (mAbs), has intensified the challenge of delivering high-concentration, high-viscosity formulations subcutaneously. Biologic therapies are typically administered parenterally, with subcutaneous (SC) injection offering significant advantages over intravenous delivery, including enabling self-administration by patients or at-home caretakers, improving therapy convenience, and reducing healthcare system costs [50]. However, developing high-concentration formulations (HCFs, ≥ 100 mg/mL) for SC administration presents substantial challenges, with viscosity representing a critical hurdle that complicates manufacturability and injectability through fine needles (27–29 G) used in prefilled syringes and autoinjectors [51].

The industry threshold of ≤2 mL was long considered the maximum limit for SC administration, but this volume threshold has been challenged in recent years, with numerous therapies now being developed for SC injection at higher volumes [50]. While concentrating drug formulations may reduce dose volumes, this strategy typically leads to more viscous solutions that require greater injection forces and longer delivery durations [50] [52]. Higher viscosity injectates are associated with greater SC tissue pressures and increased injection pressure forces, potentially impacting patient comfort, adherence, and dosing accuracy [50] [1]. This review systematically compares current and emerging device technologies capable of overcoming these challenges, providing researchers with experimental data and methodological approaches for evaluating injection performance.

Comparative Analysis of Delivery Technologies

Drug delivery technologies for high-viscosity formulations can be categorized into three primary segments based on their volume capabilities and operational mechanisms. Each category employs distinct engineering approaches to address the fundamental challenge of delivering viscous biologics through the subcutaneous route.

Table 1: Classification of High-Viscosity Delivery Technologies

Technology Category Volume Range Viscosity Range Key Mechanisms Representative Devices
Enhanced Autoinjectors 2-5 mL Up to 30 cP (standard); >50 cP (specialized) Mechanical springs, gas-powered systems BD Intevia 2.25 mL [52], YpsoMate 5.5 mL [53], SHL Maggie 5.0 mL [53]
Gas-Powered Injectors 5-20 mL >50 cP (up to 5,000 cP claimed) Compressed/liquefied gas canisters Kaléo Aerio [47] [53], CrossJect ZENEO [47], Windgap LVDC [47] [53]
On-Body Injectors (OBIs) 10-60 mL Varies with volume and duration Electromechanical motors, MEMS gas micropumps West Pharmaceutical SmartDose [54], Enable Injections enFuse [47] [54], MicroMED dBOBi [54]
Performance Comparison and Experimental Data

Direct comparison of device performance requires examination of quantitative data on delivery parameters, including injection times, force profiles, and reliability metrics across different formulation properties.

Table 2: Performance Comparison of High-Viscosity Delivery Systems

Device/Technology Max Volume (mL) Max Viscosity (cP) Injection Time Drive Mechanism Key Performance Findings
BD UltraSafe Plus 2.25 mL 2 30 Not specified Manual 95% full-dose delivery at 30 cP in human factors validation [52]
Prototype LVAI (UTW cannula) 2 50 Significantly faster than STW Mechanical spring Significantly faster delivery times vs. STW across 2.3-30 cP range; minimal tissue effects [50]
Kaléo Aerio Platform 20 Extremely high (platform claim) Variable Gas-powered Designed for large volumes of highly viscous fluids [53]
Windgap LVDC Not specified >5,000 cP (claimed) Variable Gas-powered Claims delivery of viscosities over 5,000 cP; feasibility assessments ongoing [53]
MicroMED dBOBi 50-60 Not specified Adjustable (slow infusion) MEMS gas micropump Dual-bag actuation for ULV SC delivery; half-dome design maximizes space efficiency [54]

The drive mechanism represents a fundamental differentiator between technologies. Traditional autoinjectors typically utilize mechanical springs (typically stainless steel), while emerging solutions increasingly employ gas-powered systems that provide higher energy densities than springs [47]. For ultra-large-volume (ULV) applications exceeding 25 mL, MEMS-enabled gas-pressure-driven actuators represent a novel approach, using electrochemical principles to convert electrolytes into gas pressure in a fast and controlled manner [54].

Beyond technical specifications, human factors validation remains crucial for real-world implementation. Studies with the BD UltraSafe Plus 2.25 mL demonstrated that across all studied viscosities (1-30 cP), there was no decline in usability results, with more than 95% of users expressing confidence in the safety mechanism [52]. This highlights the importance of evaluating both technical performance and user experience when selecting delivery technologies.

Experimental Protocols for Injection Performance Evaluation

Break-Loose and Extrusion Force (BLEF) Testing

Standardized measurement of injection forces provides the foundation for evaluating device performance. Break-loose and extrusion force (BLEF) tests using a tensometer that drives a plunger at constant speed while measuring varying force as the plunger moves down the syringe offer a fundamental characterization method [29]. ISO 11040-8 mandates that such tests use the complete, final system "as intended for use" and requires designers to consider how forces vary with ageing and environmental factors [29].

Protocol Implementation:

  • Equipment: Tensometer with precision balance, environmental chamber for temperature control, data acquisition system
  • Test Parameters: Constant plunger speed (typically 1-100 mm/min), controlled temperature (20-25°C), multiple batches (n≥3)
  • Key Measurements: Initial break-loose force, dynamic extrusion force, presence of air bubble expulsion signature
  • Data Analysis: Force-distance profile analysis, statistical process control for batch consistency, comparison to specification limits

The following workflow diagram illustrates the experimental and modeling approach for injection force characterization:

G A BLEF Test Setup B Constant Speed Plunger Movement A->B C Force Measurement & Data Acquisition B->C D Parameter Extraction (Break-loose, Extrusion Force) C->D E Injection Force Modeling D->E E->A Parameter Refinement F Performance Prediction E->F G Device Design Optimization F->G

Advanced modeling approaches have been co-developed to translate basic syringe test data into injection device performance. The software developed by Sanner Group and Pfizer's Devices Centre of Excellence uses a time-stepped approach to break down an injection into discrete, calculable steps, accounting for complex factors like air bubble volume changes due to pressure variations [29].

In Vivo Feasibility Assessment for Subcutaneous Delivery

For comprehensive evaluation, in vivo models provide critical insights into tissue effects, injection site leakage, and actual needle penetration depth.

Protocol Implementation [50]:

  • Animal Model: 30-40 kg anesthetized female Yorkshire swine (representative analog to human thigh and abdomen injection sites)
  • Test Formulations: Newtonian placebos with viscosity range (2.3-50 cP) using iohexol contrast solutions with dextran as viscosity modifier
  • Injection Parameters: Standardized grid pattern (six injection sites per flank), push-on-skin activation perpendicular to skin surface
  • Evaluation Metrics: Delivery time and volume, injection site leakage, injectate depot location, local tissue effects over time (histological evaluation)
  • Cannula Comparison: 27-gauge special thin wall (STW) vs. ultra-thin wall (UTW) with approximately 30% greater cross-sectional lumen area

Studies demonstrate that UTW cannulae produce significantly faster delivery times at each viscosity while maintaining effective SC delivery without quantifiable tissue leakage and with minor tissue effects that resolved within 1-2 hours [50]. This experimental approach provides critical preclinical data for device optimization.

Injection Force Modeling with Rheological Considerations

Accurate prediction of injection force requires sophisticated modeling that accounts for the rheological properties of protein solutions. An advanced injection force model consists of hydrodynamic force and friction force components [1].

Protocol Implementation [1]:

  • Hydrodynamic Force Modeling: Follows Hagen-Poiseuille law but refines approach by incorporating specific properties of drug viscosity (Newtonian and Shear-thinning) and syringe shape constant: F_hydrodynamic = 8μLA²/(πR⁴)V̄
  • Friction Force Determination: Measured through empty barrel injection force testing
  • Environmental Factors: Actual injection temperature measurement and compensation
  • Tissue Back-Pressure: Accounting for counter pressure generated by subcutaneous tissue
  • Model Validation: Comparison with experimental data across viscosity ranges (1-50 cP)

This modeling approach demonstrates that the derivation of the needle dimension constant and the rheological behavior of protein solutions represent critical parameters for accurate prediction [1]. For mAb solutions exhibiting shear-thinning behavior, this is particularly important as viscosity can dramatically reduce at high shear rates (10⁴ s⁻¹) compared with low shear rates (10 s⁻¹) [1].

Emerging Technological Approaches

Drive Mechanism Innovations

Traditional mechanical springs face limitations in delivering consistent force throughout the injection cycle, particularly for high-viscosity formulations. Emerging drive mechanisms address this challenge through novel engineering approaches:

Gas-Powered Systems: Compressed or liquefied gas canisters provide higher energy densities than springs, making them suitable for high-viscosity and/or high-volume injections [47]. Current examples include the Aerio range from Kaléo, ZENEO from CrossJect, and LVDC from Windgap Medical [47]. These systems can maintain consistent pressure throughout the injection cycle, overcoming the strong-to-weak force profile of mechanical springs.

MEMS-Enabled Gas Micropumps: Micro-electromechanical system (MEMS) technology enables the integration of mechanical and electrical components on a microscopic scale, creating miniaturized high-performance systems [54]. These pumps employ electrochemical principles to convert electrolytes into gas pressure in a fast and controlled manner, offering a simple, compact, flexible, robust, and powerful energy source for ultra-large-volume SC drug delivery systems [54].

Dual-Bag Actuation: For wearable on-body injectors, MicroMED's dBOBi system uses two flexible bags constrained inside a half-dome-shaped shell [54]. The MEMS-enabled pneumatic pump pumps gas into the first bag, transferring pressure to the second, drug-filled bag to initiate delivery. This approach enables space-efficient ULV capacity and scalability for platform device design [54].

Cannula Design and Formulation Strategies

Device technology innovations are complemented by advances in cannula design and formulation strategies that collectively address high-viscosity challenges:

Ultra-Thin Wall (UTW) Cannulae: Compared to special thin wall (STW) cannulae, UTW designs provide approximately 30% greater cross-sectional lumen area while maintaining the same external gauge size [50]. This design enhancement reduces flow resistance and enables more rapid delivery of viscous formulations with minimal tissue effects [50].

Viscosity-Reducing Agents (VRAs): Excipients including arginine·HCl, caffeine, and nicotinamide can significantly reduce formulation viscosity through synergistic combinations [51]. These agents work by modulating protein-protein interactions through complementary mechanisms, with some combinations demonstrating >90% viscosity reduction in high-concentration antibody solutions [51].

Hyaluronidase Adjuvants: The enzyme hyaluronidase temporarily degrades hyaluronic acid in the extracellular matrix, increasing tissue permeability and dispersion of injected formulations [47] [54]. This approach enables delivery of larger volumes (up to 600 mL for Ig replacement therapies) by enhancing tissue tolerance [54].

The technology selection process involves evaluating multiple parameters to match device capabilities with formulation properties:

G A Formulation Characterization (Volume, Viscosity, Stability) B Volume > 5 mL or Viscosity > 50 cP? A->B C Enhanced Autoinjector (2-5 mL, up to 50 cP) B->C No D Gas-Powered Injector (5-20 mL, >50 cP) B->D Yes E On-Body Injector (10-60 mL, variable cP) B->E Volume > 20 mL F UTW Cannula Integration C->F G VRA Formulation Optimization C->G

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful evaluation of high-viscosity delivery systems requires specific reagents, materials, and equipment. The following toolkit summarizes essential components for comprehensive device assessment.

Table 3: Research Reagent Solutions for High-Viscosity Delivery Studies

Category Specific Items Function/Application Key Characteristics
Test Formulations Iohexol contrast solutions (Omnipaque) with dextran viscosity modifier [50] Simulating biologic viscosities for device testing Newtonian placebos with confirmed viscosities (2.3-50 cP) at 20°C
Rheology Characterization Brookfield LVDV III+ rheometer with CPE-40 spindle [50] Viscosity measurement across shear rates Shear rate scans from 10% to 100% full scale range
Syringe Components BD Neopak 2.25 mL Glass Prefillable Syringe with 27G STW/UTW needles [50] [52] Primary container for formulation storage and delivery Optimized for autoinjector compatibility; UTW provides 30% greater lumen area [50]
Force Measurement Instron tensometer with precision balance, modular fixtures [30] BLEF testing per ISO 11040-8 Measures break-loose force, extrusion force, flange breakage force
Injection Force Modeling Sanner-Pfizer modeling software [29] Predicting device performance from BLEF data Time-stepped approach accounting for air bubble compression
Animal Model Yorkshire swine (30-40 kg) [50] In vivo injection site assessment Flank ID/SC tissue analogous to human thigh/abdomen

The landscape of high-viscosity drug delivery is evolving rapidly, with multiple technology platforms now capable of addressing challenges that once limited subcutaneous administration of biologics. Gas-powered injection systems and advanced on-body injectors represent the most promising approaches for the most challenging formulations, while enhanced autoinjectors with UTW cannulae continue to expand their capabilities for moderate viscosity and volume ranges.

Critical to successful development is the implementation of robust experimental protocols that integrate BLEF testing, advanced injection force modeling, and in vivo validation. The growing sophistication of predictive models enables researchers to forecast device performance and identify potential failure modes early in development, reducing the need for multiple physical prototype iterations [29]. As the field advances, the integration of MEMS technology, novel drive mechanisms, and synergistic formulation strategies will continue to push the boundaries of what can be effectively delivered through the subcutaneous route, ultimately improving patient access and convenience for high-dose biologic therapies.

Injectable microparticle drug delivery systems (DDSs), including microspheres, microcapsules, and other particulate formulations, are widely used in clinical applications for their ability to enable sustained or controlled release of therapeutics, reduce injection frequency, and improve drug stability [16]. Despite these therapeutic advantages, administering these systems via conventional hypodermic needles presents significant challenges related to injectability—a term encompassing performance during injection, including the pressure or force required, evenness of flow, and freedom from clogging [16]. Inefficient injection can lead to issues such as needle clogging, high residual drug amounts in the syringe, and inaccurate dosing, which ultimately hamper clinical translation and patient compliance [16] [55] [56].

This guide objectively compares the performance of microparticle systems based on critical parameters affecting their injectability, framed within broader research on injection force measurement. We summarize experimental data investigating the effects of particle size, needle gauge, suspension viscosity, and injection speed on key injectability metrics: injection force and discharge rate (the actual percentage of microparticles successfully delivered) [16] [55]. Supporting data from controlled in vitro and in vivo experiments, along with predictive modeling frameworks, are provided to aid researchers in optimizing their formulations and administration protocols.

Comparative Analysis of Injectability Parameters

The injectability of microparticle suspensions is not determined by a single factor but by the complex interplay of particle characteristics, suspension properties, and device geometry. The following comparative analysis synthesizes key findings from recent experimental studies.

Impact of Critical Parameters on Injectability

Table 1: Comparative Influence of Formulation and Device Parameters on Injectability Metrics

Parameter Impact on Injection Force Impact on Discharge Rate/Injectability Key Experimental Findings
Needle Gauge (Inner Diameter) Smaller gauges (finer needles) substantially increase required force [16]. Identified as the most influential factor; smaller gauges drastically reduce injectability [16] [55]. A shift from an 18G to a 21G needle caused injectability to drop by nearly half for certain particle concentrations [55].
Particle Size Larger particles increase injection force [16]. Larger particle sizes result in poor injectability, with a more pronounced effect in smaller needles [16] [55]. In a 21G needle, increasing average particle diameter from 50 µm to 200 µm reduced injectability from 71% to 35% [55].
Suspension Viscosity Higher viscosity linearly increases injection force, especially at higher injection rates [16] [42]. Moderate increase (from water to 1% MC) can boost injectability by >50%; further increases have diminishing returns and can hinder practicality [16] [55]. Injection force for a 20 mPa·s solution ranged from 1.8 N to 4.7 N as the injection rate increased from 0.025 mL/s to 0.2 mL/s [42].
Particle Concentration Not explicitly detailed in results. Higher concentrations decrease injectability, with a sharp drop after a certain threshold [55]. Injectability was similar for 250 and 500 particles per volume, and for 800 and 1000 particles, but significantly lower for the higher concentration group [55].
Injection Speed/Rate Higher injection speeds significantly increase the required injection force [16] [42]. Vehicle viscosity and injection speed have varying effects on discharge rate [16]. For a 20 mPa·s solution, increasing injection rate from 0.025 mL/s to 0.2 mL/s raised average force from 1.8 N to 4.7 N [42].
Particle Shape Not a major independent influence in the range studied [55]. Within the range studied (spheres, cubes, cylinders), shape did not independently influence overall injectability [55]. Computational simulations revealed that shape was less critical than size, concentration, or needle gauge [55].

Optimized Formulation and Device Conditions

Research by Zhao et al. aimed to establish a system with lower injection force and higher discharge rate. Through a Design of Experiment (DOE) approach, they identified an optimized window for injectability [16] [57]:

  • Suspension Concentration: 120–240 mg/mL
  • Vehicle Viscosity: ~60 cP at 20°C
  • Needle Gauge: 23-gauge

This optimized formulation was verified in vivo in rats, proving that the Levonorgestrel (LNG) microsphere suspension exhibited good injectability when injected into subcutaneous tissue [16].

Experimental Protocols for Assessing Injectability

To ensure reproducible and clinically relevant results, standardized experimental protocols for evaluating injectability are essential. The following methodologies are commonly employed in the field.

Measurement of Injection Force and Discharge Rate

Injection Force Measurement:

  • Apparatus: A mechanical tester (e.g., a texture analyzer or universal testing machine) is used to depress the syringe plunger at a controlled rate. The force required to maintain this rate is recorded in real-time [16] [42].
  • In Vivo Consideration: When measuring forces in vivo, the contribution of tissue back-pressure must be accounted for. This back-pressure increases linearly with viscosity and injection rate and can exhibit significant variability [42]. Studies in minipigs have shown that the tissue contribution can range from <1 N for low-viscosity solutions at slow rates to over 12 N for higher viscosities and faster rates [42].

Discharge Rate Calculation:

  • The discharged rate is a critical metric for dose accuracy and is calculated as the percentage of microparticles successfully delivered through the needle [16] [55].
  • Method: The mass or number of particles in the syringe is measured before and after injection. The discharged rate is calculated using the formula: (Mass_initial - Mass_residual) / Mass_initial × 100% [16]. Alternatively, the collected effluent can be analyzed to count the number of particles injected [55].

Advanced Predictive Modeling Framework

Beyond physical experiments, a computational modeling framework has been established to predict and optimize injectability.

  • Computational Fluid Dynamics (CFD): A multiphysics model coupling CFD with microparticle transport can simulate particle flow and needle blockage in a syringe-needle system. This model explores the effect of parameters like particle size, shape, concentration, needle gauge, and solution viscosity [55].
  • Machine Learning: Experimental data can be incorporated into an Artificial Neural Network (ANN) to create a predictive model. Researchers can input parameters (e.g., particle size, concentration, viscosity, needle size) and receive a prediction of injectability, saving significant experimental time [55] [56]. This approach also allows for the exploration of novel syringe designs that maximize injectability [55] [56].

G Microparticle Injectability Evaluation Workflow Start Start: Define Formulation & Device Parameters Exp In Vitro/In Vivo Experiments Start->Exp CFD Computational Fluid Dynamics (CFD) Modeling Start->CFD Data Data Collection: Injection Force & Discharge Rate Exp->Data CFD->Data ANN Machine Learning (ANN) Training Data->ANN Model Validated Predictive Model ANN->Model Model->Start Opt Output: Optimized Formulation & Device Design Model->Opt Feedback Loop

Experimental and Computational Workflow for Evaluating Microparticle Injectability. An integrated approach using both physical experiments (in vitro and in vivo) and computational modeling (CFD) feeds data into a machine learning model (ANN) to create a predictive tool for optimization [55].

The Scientist's Toolkit: Essential Research Reagents and Materials

Selecting appropriate materials is fundamental for developing and evaluating injectable microparticle systems. The table below details key reagents and their functions as identified in the research.

Table 2: Key Research Reagent Solutions for Microparticle Injectability Studies

Material/Reagent Function in Research Examples from Literature
Model Microparticles Used to systematically study the impact of size, shape, and surface properties on injectability. Levonorgestrel (LNG) microspheres (drug-loaded), glass beads (smooth, spherical), mesoporous silica (irregular shape) [16]. A library of micromolded particles (cubes, cylinders, spheres) in the 80-325 µm range [55].
Viscosity-Modifying Agents Dissolved in the suspension vehicle to control rheological properties, prevent particle sedimentation, and study the effect of viscosity on injection force and flow. Sodium Carboxymethyl Cellulose (CMC-Na) [16]. Methylcellulose (MC) at concentrations of 1% and 2.5% [55].
Syringe and Needle Systems The primary delivery device; varying gauge (G), length, and internal geometry to assess clogging and flow resistance. Standard 1 mL and 3 mL syringes with Luer-Lok [16]. Needles ranging from 18G to 27G [16] [55]. Custom-designed syringe with a nozzle-like taper to improve injectability [55] [56].
Characterization Instruments Used to measure fundamental properties of particles and suspensions that correlate with injectability. Mechanical Testers: For measuring injection force [16]. Scanning Electron Microscope (SEM): For visualizing particle size and surface morphology [16]. Rheometer: For measuring suspension viscosity and flow behavior [16].

The injectability of microparticle drug delivery systems is a critical attribute that demands careful consideration during formulation and device design. Evidence consistently shows that needle gauge and particle size are the most dominant factors, with smaller needles and larger particles dramatically increasing the risk of clogging and reducing the discharged dose. While increasing suspension viscosity can mitigate sedimentation and improve injectability to a point, it concurrently raises the required injection force, necessitating a careful balance.

The adoption of a comprehensive evaluation strategy that integrates traditional in vitro and in vivo experiments with modern computational modeling and machine learning provides a powerful framework for addressing injectability challenges. By systematically applying these insights and protocols, researchers can de-risk the development of microparticle-based therapies, enhance their clinical translation, and ensure reliable and accurate dosing for patients.

In the field of drug delivery, desiliconisation refers to the chemical and physical degradation of silicon-based components, a phenomenon critically linked to device performance and longevity. This process is particularly relevant for porous silicon (PSi) drug carriers and silicone-based elastomers used in injectable devices, where material changes over time can directly impact critical performance parameters like injection force. Within the context of a broader thesis on injection force measurement, understanding desiliconisation is paramount. The degradation of silicon-based materials can alter the frictional dynamics between a syringe plunger and barrel, the flow resistance of a drug formulation through a needle, and the overall mechanical integrity of the delivery system. This guide objectively compares the performance of different silicon-based drug delivery platforms, examining their susceptibility to desiliconisation and presenting experimental data on how this aging process affects their functional characteristics, with a specific focus on implications for delivery force.

Silicon-Based Platforms in Drug Delivery: A Comparative Analysis

Porous Silicon (PSi) Drug Carriers

Porous Silicon (PSi) is an electrochemically engineered material with a tunable nanostructure that serves as a versatile host for therapeutic compounds [58]. Its high surface area and modifiable surface chemistry make it an attractive candidate for controlled release applications. The desiliconisation of PSi in a physiological context is not a detriment but a designed feature; it is a biodegradable material whose degradation products are primarily orthosilicic acid (Si(OH)4), the form of silicon naturally found in the body, which is generally considered biocompatible [59].

Table 1: Comparison of Porous Silicon Drug Delivery Platforms

Platform Characteristic Electrochemically Etched PSi Stain-Etched PSi
Fabrication Method Anodic etching of Si wafer in HF electrolyte [59] Chemical oxidation in HF/HNO3 solution [59]
Pore Size Control High (1 nm to >1 μm); precise layered structures possible [59] Lower, less reproducible [59]
Structural Complexity Can fabricate complex structures (e.g., photonic crystals) [59] Limited to simple powders [59]
Biodegradation Rate Tunable via pore size, porosity, and surface chemistry [59] Less controllable [59]
Primary Desiliconisation Pathway Hydrolysis of Si backbone to soluble silicic acid [59] Hydrolysis of Si backbone to soluble silicic acid [59]
Typical Drug Release Profile Sustained release over hours to days [58] Less characterized

Silicone Elastomers in Medical Devices

Beyond PSi carriers, silicones (polydimethylsiloxane, PDMS) are ubiquitous as elastomeric components in drug delivery systems, such as syringe plungers and seals. The aging of these materials is a critical factor in device performance. Desiliconisation in this context is an oxidative or chemical process that alters the polymer network. Research has shown that thermal aging of PDMS rubbers leads to macromolecular and mechanical changes, which can be tracked by sol-gel measurements and uniaxial tensile testing [60]. These changes directly impact mechanical properties like elasticity and hardness, which in turn can affect the plunger force required for injection.

Experimental Protocols for Studying Desiliconisation and Its Effects

Protocol 1: In Vitro Degradation and Drug Release of PSi

This protocol assesses the desiliconisation rate of PSi carriers and its correlation with drug release kinetics [59] [58].

  • Material Fabrication: Prepare PSi films via electrochemical etching of a p-type silicon wafer in an HF-based electrolyte. Apply a current density program to achieve the desired porosity and pore size. Lift off the film using an electropolishing pulse and fracture into microparticles via ultrasonication [59].
  • Surface Modification: Functionalize a portion of the PSi particles with thermal oxidation (heating in air to form a hydrophilic SiO(_x) surface) or hydrosilylation (reacting with an alkene to form a stable Si-C bound hydrophobic layer) [58].
  • Drug Loading: Incubate the PSi particles in a concentrated solution of the model drug (e.g., dexamethasone, ibuprofen) under vacuum to facilitate infusion into the pores. Separate the loaded particles and remove surface-adsorbed drug by brief washing [58].
  • In Vitro Degradation/Release: Place a measured mass of drug-loaded PSi particles in a phosphate-buffered saline (PBS) solution at 37°C under gentle agitation. At predetermined time points, centrifuge the suspension and analyze the supernatant.
    • Desiliconisation Measurement: Quantify the concentration of released silicon in the supernatant using the molybdate blue method (UV-Vis spectroscopy) [59].
    • Drug Release Measurement: Quantify the concentration of the released drug in the supernatant using HPLC or fluorescence spectroscopy [58].
  • Data Analysis: Plot cumulative silicon and drug release over time. A strong correlation indicates that drug release is governed by the desiliconisation (degradation) of the PSi matrix.

Protocol 2: Accelerated Aging of Silicone Elastomers and Injection Force Analysis

This protocol evaluates the mechanical changes in silicone components under accelerated aging and their impact on syringe functionality.

  • Sample Preparation: Obtain standardized specimens (e.g., O-rings, miniature slabs) of medical-grade PDMS elastomer.
  • Accelerated Aging: Subject specimens to thermal oxidative aging in an air-circulating oven at a elevated temperature (e.g., 250°C) for varying durations (e.g., 0, 24, 48, 96 hours) [60].
  • Mechanical Characterization:
    • Uniaxial Tensile Testing: Test aged and unaged specimens per ASTM D412. Measure the stress-strain curves to determine the ultimate tensile strength (UTS) and elongation at break [60].
    • Cross-link Density (Sol-Gel Analysis): Weigh a sample of aged elastomer (W(i)), swell it in a good solvent (e.g., toluene) for 24-48 hours, blot dry, and re-weigh (W(s)). Then, dry the sample to constant weight (W(_d)) to determine the gel fraction and infer cross-link density [60].
  • Injection Force Measurement:
    • Apparatus: Use a syringe force measurement kit (e.g., Loadstar Sensors REB5 load cell with DI-1000U interface and LoadVUE Pro software) to measure plunger actuation force [61].
    • Method: Assemble syringes with aged and unaged silicone plungers. Fill with a standard viscosity fluid (e.g., 1% w/v methylcellulose in water). Mount the syringe on a test stand and connect the plunger to the load cell. Actuate the plunger at a constant speed (e.g., 10 mm/min) and record the force versus displacement data [61].
  • Data Correlation: Correlate the measured break-loose and glide forces with the mechanical properties (e.g., hardness from tensile test, cross-link density) of the aged elastomers.

Table 2: Key Research Reagent Solutions and Materials

Item Function/Description Experimental Role
Hydrofluoric Acid (HF) Electrolyte for silicon etching [59] Forms porous structure in PSi fabrication.
p-type Silicon Wafer Substrate for PSi formation [59] Source material for creating porous silicon.
Load Cell Force Gauge Digital force transducer (e.g., REB5) [61] Precisely measures syringe plunger actuation force.
Phosphate Buffered Saline (PBS) Aqueous salt solution, pH 7.4 Simulates physiological conditions for degradation/release.
Polydimethylsiloxane (PDMS) Medical-grade silicone elastomer [60] Model material for studying aging of plungers/seals.
Toluene Organic solvent Used for sol-gel analysis to measure polymer cross-linking [60].

Modeling the Impact of Desiliconisation on Device Performance

The data gathered from the described protocols allows for the development of predictive models. For PSi carriers, a kinetic model can be established linking pore surface area, surface chemistry, and environmental pH to the rate of silicate hydrolysis and, consequently, drug release. For silicone elastomers, an empirical-mechanical model can correlate the chemical changes (e.g., increased cross-link density from post-curing or chain scission from oxidation) to the increase in plunger friction and injection force. These models are essential for predicting device shelf-life and ensuring consistent performance throughout a product's intended lifespan.

G cluster_aging Device Aging Factors cluster_material Material-Level Changes cluster_mechanical Mechanical & Functional Effects cluster_output Measurable Performance Output A Thermal Oxidation C Increased Cross-Link Density (Silicone) A->C D Polymer Chain Scission A->D B Hydrolytic Degradation B->D E Pore Structure Alteration (PSi) B->E F Increased Plunger Stiffness & Friction C->F D->F G Altered Drug Release Kinetics E->G H Increased Break-Loose and Glide Force F->H I Change in Delivery Dosage/Profile G->I

Desiliconisation Impact on Device Performance

The process of desiliconisation is a critical factor in the performance and reliability of silicon-based drug delivery systems. As demonstrated, the aging of porous silicon carriers and silicone elastomers follows distinct pathways but ultimately leads to measurable changes in device function. For researchers focused on injection force measurement, understanding and modeling the chemical and mechanical degradation of these materials is essential for designing robust devices, predicting their in-use performance, and ensuring the safe and effective delivery of therapies. The experimental protocols and data presented provide a framework for the objective comparison of different material platforms and their resilience to the aging processes inherent in drug delivery.

Optimizing Syringe-Needle Combinations for Minimal Force and Maximum Comfort

Injection force is a critical parameter in drug delivery, directly impacting patient comfort, adherence to treatment regimens, and the feasibility of self-administration. The optimization of syringe-needle combinations represents a significant focus in pharmaceutical development, particularly with the increasing prevalence of high-viscosity biologic therapies. The biomechanical interaction between syringe caliber, needle gauge, plunger mechanics, and fluid properties determines the injection experience. This guide provides a comparative analysis of syringe-needle systems based on empirical force measurement data, offering researchers and developers evidence-based selection criteria for various clinical and formulation requirements.

Fundamentals of Injection Force

Injection force is quantified through two primary parameters: the initial force required to overcome static friction (break-loose force) and the sustained force needed to maintain plunger movement (glide force).

  • Plunger-Stopper Break Loose Force (PBF): The maximum force required to initiate movement of the plunger from its static position within the syringe barrel. This force overcomes the static friction between the plunger stopper and the syringe barrel [7] [4].
  • Dynamic Gliding Force (DGF): The force required to maintain continuous movement of the plunger once initial static friction has been overcome. This force is influenced by both the dynamic friction of the plunger and the fluid dynamics of the formulation passing through the needle [7] [44].

These forces are critically influenced by multiple factors including syringe barrel diameter, needle gauge and length, plunger stopper design, silicone oil lubrication, and formulation viscosity [44] [62] [4]. Understanding these relationships enables systematic optimization of injection systems for specific therapeutic applications.

Comparative Performance Data

Syringe Size and Needle Gauge Interdependence

Experimental data demonstrates significant variation in injection forces across different syringe-needle combinations. The following table summarizes key findings from controlled laboratory studies:

Table 1: Injection Force Comparison Across Syringe-Needle Combinations

Syringe Size Needle Gauge Break-Loose Force (N) Glide Force (N) Key Findings
1 mL [7] 26G (Original) 1.15 (SD 0.22) 0.13 (SD 0.05) Best overall combination with lowest maintenance force
1 mL [7] 27G Spinal 0.75 (SD 0.087) 0.36 (SD 0.05) Lowest initial force despite longer needle length
1 mL [7] 30G 0.80 (SD 0.12) 0.71 (SD 0.06) High glide force makes combination less desirable
3 mL [7] 23G (Original) 4.82 (SD 0.28) 3.59 (SD 0.13) Significantly higher forces than 1 mL equivalents
5 mL [7] 22G (Original) 18.90 (SD 1.20) 20.30 (SD 0.36) Forces may approach thumb force limits for some users
10 mL [7] 30G 23.90 (SD 1.90) 26.10 (SD 0.85) Highest recorded forces; challenging for manual injection
Needle Gauge, Length, and Wall Thickness Optimization

Advanced needle designs with optimized wall thickness demonstrate significant improvements in injection performance, particularly for viscous formulations:

Table 2: Impact of Needle Design on Injection Time for Viscous Formulations

Needle Configuration Viscosity (cP) Injection Time (seconds) Performance Notes
27G UTW 8 mm [62] 11 3.63 Fastest configuration at low viscosity
27G STW ½ inch [62] 11 6.08 40% longer than UTW due to length and wall thickness
27G UTW 8 mm [62] 53 17.20 Maintains performance at high viscosity
27G STW ½ inch [62] 53 31.58 84% longer than UTW at high viscosity
29G Tapered Needle [8] Varies Significant reduction vs. standard 29G Superior for shear-thinning non-Newtonian fluids

UTW: Ultra-Thin Wall; STW: Special Thin Wall

The data indicates that smaller syringes (1mL) generate substantially lower injection forces than larger syringes (3-10mL) when paired with the same needle gauge [7]. For keloid injections requiring significant force, a 1mL syringe with a 25G, 16mm needle provided the most ergonomic combination, requiring only 64.8% of maximum female thumb force compared to 103.5% for a standard combination [63].

Transitioning from 29-gauge to 27-gauge needles reduced glide force by 59% (32N → 13N) during administration of 1mL of 20-centipoise viscous fluid [44]. Tapered needle technology (29G TNN) demonstrated injection forces lower than 29G thin-wall needles and similar to 27G thin-wall needles for Newtonian solutions, with particular advantages for shear-thinning non-Newtonian solutions [8].

Experimental Protocols for Injection Force Measurement

Standardized Force Measurement Methodology

Robust measurement of injection forces requires standardized methodologies and equipment. The following experimental workflow represents the consensus approach across multiple studies:

G Syringe Preparation Syringe Preparation Machine Setup Machine Setup Syringe Preparation->Machine Setup Parameter Configuration Parameter Configuration Machine Setup->Parameter Configuration Force Measurement Force Measurement Parameter Configuration->Force Measurement Data Analysis Data Analysis Force Measurement->Data Analysis Performance Evaluation Performance Evaluation Data Analysis->Performance Evaluation

Diagram 1: Injection Force Measurement Workflow

Key methodological components include:

  • Equipment Standardization: Universal testing machines (e.g., Instron 5940 Series, Zwick UTM) with calibrated load cells capable of measuring forces up to 200N with ±0.5% accuracy are employed [7] [4]. These systems provide the precision required for reliable force quantification.

  • Test Parameters: A constant plunger speed between 50-100 mm/min is typically used, simulating realistic injection conditions [7] [4]. Each syringe-needle combination is tested multiple times (typically n=3-20) to ensure statistical significance.

  • Environmental Controls: Testing under standardized temperature conditions is essential as viscosity is temperature-dependent. Some protocols include testing after cold storage (2-8°C) to simulate real-world conditions [64].

  • Data Capture: Force-distance charts are generated, capturing the break-loose force (0-2mm plunger movement) and glide force (sustained movement) automatically via associated software [29] [4].

Human Factors Integration

Beyond mechanical testing, comprehensive evaluation incorporates human factors to assess real-world usability:

  • Simulated Administration: Studies with diverse cohorts (n=12+) evaluate usability perceptions correlated with glide force reductions [44].
  • Thumb Force Capability: Comparison of injection forces to maximum thumb force exertion capabilities, particularly relevant for patient populations with limited hand strength [63].
  • Visual Confirmation: High-speed cameras (50 frames per second) track plunger movement to precisely measure injection time from activation to complete dose expulsion [62].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Materials for Injection Force Research

Item Function Specification Examples
Universal Testing Machine [7] [4] Precisely measures force during plunger activation Instron 5940 Series, Zwick UTM with 200N load cell
Prefillable Syringes [44] [62] Primary container for formulation testing SCHOTT Pharma, BD Neopak, Stevanato Group Alba/Nexa
Needle Variants [7] [62] Varies flow resistance; critical for force optimization 25G-30G; thin-wall (TW), special thin-wall (STW), ultra-thin wall (UTW)
Viscosity Standard Solutions [44] [62] Simulates biologic formulation behavior PEG solutions, placebo formulations (1-70 cP range)
Force Measurement Software [29] [4] Data acquisition and analysis testXpert III, custom modeling software for prediction
Model Protein Solutions [8] Represents real-world biologic formulations Monoclonal antibodies, immunoglobulin solutions

The optimization of syringe-needle combinations for minimal injection force involves balancing multiple design parameters. The evidence consistently demonstrates that smaller syringe diameters (1mL) generate significantly lower injection forces than larger syringes when paired with identical needles. For viscous formulations, needle inner diameter (optimized through thin-wall technologies) exerts a greater influence on injection force than needle length. Advanced needle designs, including tapered and thin-wall configurations, provide substantial improvements in injectability, particularly for high-concentration biologic therapies requiring patient self-administration. These findings provide a foundation for evidence-based selection of injection systems, ultimately contributing to enhanced patient comfort, improved adherence, and successful drug delivery across diverse therapeutic areas.

From Bench to Patient: Validating Performance and Ensuring Clinical Success

Correlating Laboratory Force Measurements with Human Panel Testing

In the development of injectable drug delivery systems, a critical challenge persists: translating precise laboratory force measurements into predictable human injection experiences. Laboratory force measurements provide quantitative, reproducible data on the mechanical performance of drug delivery systems, measuring parameters such as break-loose force and gliding force during injection. Meanwhile, human panel testing offers qualitative, subjective insights into patient comfort, usability, and perceived pain. The correlation between these datasets is essential for developing patient-centric drug delivery devices that are both technically efficient and well-tolerated by end-users.

This correlation is becoming increasingly vital as pharmaceutical formulations grow more complex. The rise of high-viscosity biologics and large-volume subcutaneous injections has intensified the need for delivery systems that can manage challenging mechanical properties while maintaining patient comfort [33] [65]. Furthermore, the expanding market for self-injection devices for chronic conditions places greater emphasis on human factors and usability [66] [46]. This guide examines the methodologies, relationships, and practical applications connecting laboratory force data with human testing outcomes across different drug delivery platforms.

Laboratory Force Measurement Fundamentals

Key Parameters and Measurement Techniques

Laboratory force analysis characterizes the mechanical behavior of drug delivery systems through several standardized parameters:

  • Break-loose force (BL): The initial force required to overcome static friction and initiate plunger movement within a syringe barrel. This parameter is particularly crucial for autoinjector systems, where spring forces must reliably overcome this initial resistance [33].
  • Gliding force (GF): The sustained force required to maintain consistent plunger movement throughout the injection process. Elevated gliding forces can indicate issues with syringe siliconization, formulation viscosity, or component compatibility [33].
  • Injection force: The comprehensive force profile required to complete drug delivery, influenced by needle geometry, formulation viscosity, and device mechanics [16].

These parameters are typically measured using dynamic mechanical test systems equipped with load cells and precision actuators. Advanced systems integrate additional sensors, including acoustic click detectors to identify activation events and cameras to visually document drug delivery confirmation windows [30].

Standards and Regulatory Frameworks

Laboratory force measurement protocols are guided by international standards that ensure consistency and reliability:

  • ISO 11040-4 and ISO 11040-8 for pre-filled syringes
  • ISO 11608-1,5,6 for needle-based injection systems
  • USP 382 and 1382 for container closure systems [30]

These standards provide the foundation for reproducible testing methodologies across the pharmaceutical industry.

Human Panel Testing Methodologies

Study Design and Participant Selection

Human panel testing for injectable devices employs structured methodologies to capture subjective user experiences:

HumanPanelTesting Human Panel Testing Human Panel Testing Participant Selection Participant Selection Study Protocol Study Protocol Participant Selection->Study Protocol Young Adults (18-40) Young Adults (18-40) Participant Selection->Young Adults (18-40) Screened for Sensitivity Screened for Sensitivity Participant Selection->Screened for Sensitivity Representative Sample Representative Sample Participant Selection->Representative Sample Data Collection Data Collection Study Protocol->Data Collection Controlled Environment Controlled Environment Study Protocol->Controlled Environment Reference Product Use Reference Product Use Study Protocol->Reference Product Use Standardized Scoring Standardized Scoring Study Protocol->Standardized Scoring Analysis & Correlation Analysis & Correlation Data Collection->Analysis & Correlation Pain & Comfort Scales Pain & Comfort Scales Data Collection->Pain & Comfort Scales Usability Assessment Usability Assessment Data Collection->Usability Assessment Device Preference Device Preference Data Collection->Device Preference Acceptance Value Calculation Acceptance Value Calculation Analysis & Correlation->Acceptance Value Calculation Force-Preference Correlation Force-Preference Correlation Analysis & Correlation->Force-Preference Correlation Statistical Modeling Statistical Modeling Analysis & Correlation->Statistical Modeling

Figure 1: Human panel testing workflow demonstrates the structured approach from participant selection through to data analysis and correlation with laboratory measurements.

Human panel testing requires careful design to generate meaningful, reproducible data. While the ideal participants would come from the target patient population, ethical considerations and practical constraints often make this challenging, particularly for novel active pharmaceutical ingredients [67]. Therefore, most studies utilize young adults (ages 18-40) as participants, as this demographic demonstrates taste sensitivity and sensory perception similar to broader populations [67].

These participants should be screened for sensitivity thresholds and need not be experts in sensory evaluation, provided that a reference product is used during assessment to calibrate responses [67]. Studies are conducted in controlled environments with standardized protocols to minimize variables and ensure data quality.

Assessment Criteria and Scoring Systems

Human panel assessments typically evaluate multiple dimensions of the injection experience:

  • Pain and discomfort levels using standardized pain scales
  • Ease of use and perceived complexity of device operation
  • Ergonomic comfort and device handling characteristics
  • Overall preference when comparing multiple device options
  • Psychological factors such as anxiety reduction, particularly with features like shorter needles [33]

For robust evaluation during development, researchers implement structured scoring systems and calculate acceptance values to determine whether formulations should progress in development pipelines [67].

Correlation Approaches and Experimental Data

Establishing Force-Comfort Relationships

The relationship between laboratory measurements and human perception follows predictable patterns, though with important nuances:

Table 1: Correlation Between Laboratory Force Data and Human Perception

Laboratory Parameter Human Perception Correlation Optimal Range Study Details
Break-loose Force High correlation with initial injection discomfort Minimize while maintaining reliability Critical for autoinjector spring force design [33]
Gliding Force Correlates with injection smoothness and ease Consistent profile, <20N for manual devices Affected by silicone coating, viscosity [33]
Injection Force Direct impact on perceived pain and effort Device-dependent: <10-15N for manual injection 25% reduction with optimized needles showed clear preference [33]
Force Variability Perceived as unreliable or jarring experience Consistent force profile throughout Human factors studies detect subtle issues [30]

Research demonstrates that force reductions achieved through device optimization directly translate to improved user preference. Human factors studies conducted by Stevanato Group revealed a clear preference for 8mm STW needles over conventional options, with participants citing both reduced injection force and the psychological benefit of shorter needle length as contributing factors [33].

Integrated Testing Protocols

Correlative studies employ structured methodologies to directly link mechanical data with human experience:

Table 2: Experimental Protocols for Correlation Studies

Protocol Phase Methodology Data Collected Correlation Analysis
Device Characterization Mechanical testing per ISO standards Break-loose force, gliding force, injection force profile Establish baseline performance metrics
Human Factors Testing Controlled administration with representative user panel Pain scores, ease-of-use ratings, preference data Statistical analysis of force-preference relationship
Component Optimization Iterative testing of design variations (e.g., needle geometry, lubrication) Force measurements and human ratings for each variant Identify design parameters with strongest human impact
Validation Comparative testing against reference products Acceptance values, performance benchmarks Verify correlation models predict real-world preference

These protocols enable researchers to move beyond simple force thresholds to develop nuanced understanding of how specific force characteristics influence human perception. For instance, studies have demonstrated that needle gauge represents the most significant factor influencing injectability in microparticle delivery systems, substantially impacting both injection force and discharge rate [16].

Application Across Delivery Systems

Pre-filled Syringes and Autoinjectors

For pre-filled syringes and autoinjectors, force management focuses on plunger movement dynamics and needle geometry. The interface between the plunger and syringe barrel creates friction that must be optimized through:

  • Barrel siliconization techniques, including cross-linked silicone coatings that maintain stability with aggressive surfactants [33]
  • Plunger design features such as three-rib configurations that maintain continuous barrel contact for smooth pressure distribution [33]
  • Needle optimization through shorter lengths (e.g., 8mm) and specialized thin-wall designs that reduce hydrodynamic resistance [33]

Human studies consistently show that reductions in injection force directly correlate with improved user preference and reduced anxiety, particularly for self-administered therapies [33].

Advanced Delivery Systems

Emerging delivery platforms present unique force management challenges:

  • Wearable on-body delivery devices must manage large-volume (5-20mL) biologics with potentially high viscosity over extended administration periods [65]
  • Microparticle delivery systems face additional complexities including particle sedimentation and needle clogging, which impact both injection force and discharge rate [16]
  • Connected injector systems introduce additional design constraints but enable data collection on real-world device use patterns [68] [46]

Each system requires tailored approaches to balance mechanical requirements with human factors considerations.

The Researcher's Toolkit

Essential Research Equipment and Reagents

Table 3: Essential Research Tools for Force and Human Correlation Studies

Tool Category Specific Examples Function in Research Application Notes
Force Measurement Systems Instron systems with specialized fixtures Quantify break-loose force, gliding force, injection force Integrated balances measure delivered volume; acoustic sensors detect clicks [30]
Human Factors Testing Facilities Controlled clinical environments with standardized assessment tools Collect subjective pain, comfort, and preference data Must screen participants for sensitivity thresholds; use reference products [67]
Advanced Sensors Acoustic click detectors, integrated cameras Objectively document device feedback mechanisms Superimpose sound data on force profiles; correlate visual cues with timestamps [30]
Formulation Tools Rheometers, particle characterization systems Characterize viscosity, particle size and distribution Particle size and needle gauge significantly impact injectability [16]
Data Integration Platforms Statistical analysis software, AI/ML algorithms Identify correlations between force data and human responses Artificial neural networks can model complex relationships [67]
Emerging Technologies and Methodologies

The field of correlation research is advancing through several innovative approaches:

  • Artificial Neural Networks (ANNs) can model complex relationships between formulation properties, device parameters, and human perception, potentially predicting acceptability without extensive human testing [67]
  • Digital biomarkers and wearable technology enable real-world monitoring of device use and patient responses outside controlled clinical settings [69]
  • Advanced in vitro models including organ-on-a-chip systems and human tissue testing provide human-relevant data without the ethical challenges of full human trials [70]

These technologies promise to enhance the efficiency and predictive power of correlation research while potentially reducing development timelines.

Correlating laboratory force measurements with human panel testing represents a critical capability in developing patient-centric drug delivery systems. Through structured experimental protocols that integrate mechanical testing with human factors evaluation, researchers can establish predictable relationships between quantitative force parameters and qualitative user experiences. The continuing evolution of biologic therapies, with their associated challenges of high viscosity and large volume administration, makes this correlation increasingly vital. By leveraging the methodologies, data, and insights presented in this guide, drug development professionals can optimize delivery systems to balance technical requirements with human factors, ultimately improving patient adherence, comfort, and therapeutic outcomes.

In the development of modern drug delivery systems, particularly for injectable biologics, establishing clinically relevant force thresholds is paramount for ensuring patient safety, adherence, and therapeutic efficacy. The administration force required to expel a drug formulation from a device—such as a prefilled syringe (PFS) or autoinjector—directly impacts a patient's ability to successfully self-administer treatment and their comfort during the process [4]. Excessive force can lead to incomplete dosing, patient anxiety, physical discomfort, and even device failure [49]. This case study examines the methodologies for quantifying these forces, analyzes performance data across different delivery systems, and establishes the critical thresholds that define an optimal user experience within the context of a broader research thesis on injection force measurement.

The shift toward patient-centric care and self-administration for chronic conditions like diabetes, multiple sclerosis, and rheumatoid arthritis has intensified the focus on device usability [71] [66]. High-viscosity formulations of monoclonal antibodies and other biologics, often exceeding 20 centipoise (cP), present significant challenges as they increase the resistance to flow, consequently raising the injection force required [49]. Therefore, optimizing the entire delivery system—from the drug formulation and primary container to the device's drive mechanism—is essential to maintain injection forces within a clinically acceptable and patient-friendly range.

Experimental Protocols for Force Measurement

Standardized testing protocols are the foundation for generating reliable and comparable force data. These methodologies allow researchers to characterize device performance and identify potential failure modes under controlled conditions.

Break-Loose and Glide Force Measurement

The Break-Loose and Extrusion Force (BLEF) test is a cornerstone for evaluating prefilled syringes. This test characterizes the forces required to initiate and maintain plunger movement [4] [29].

  • Apparatus: A universal testing machine (UTM) equipped with a calibrated load cell (e.g., 200 N capacity) is used. The system should include specialized fixtures to hold the syringe and actuate the plunger [30] [4].
  • Standard Protocol: Following ISO 11040-4 guidelines, the plunger is advanced at a constant speed (typically 50 mm/min for a specified distance, e.g., 18.2 mm) while the force is recorded in newtons (N) [4].
  • Key Metrics:
    • Break-Loose Force (First Fmax): The peak force required to overcome static friction and initiate plunger movement from its rest position (measured over the first 0-2 mm of travel) [4].
    • Glide Force (Fav): The average force required to sustain plunger movement after initiation (measured over a specified glide region, e.g., 2-18.2 mm) [4].
  • Data Integration: Modern systems integrate additional sensors, such as microphones for auditory click detection and cameras to verify drug delivery through the window, synchronizing this data with the force profile for comprehensive analysis [30].

Performance Testing with Autoinjectors

When a PFS is integrated into an autoinjector, testing must account for the dynamics of the device's drive mechanism, typically a spring.

  • Methodology: Autoinjectors are activated in a controlled fixture, and a high-speed camera (e.g., 50 frames per second) tracks the plunger rod movement to precisely measure injection time from activation to full dose expulsion [49].
  • Variable Analysis: Tests are repeated across multiple batches (e.g., n=20 per configuration) with different formulation viscosities and needle specifications (gauge, length, wall thickness) to understand performance boundaries [49].
  • Ageing Studies: To simulate end-of-shelf-life performance, syringes are subjected to desiliconization studies, which increase plunger-syringe friction and represent a worst-case scenario for force requirements [29].

Comparative Performance Data Analysis

Quantitative data reveals how specific device and formulation choices directly impact the forces experienced during administration.

Prefilled Syringe Force Profiles

Data from functional testing of PFSs containing a monoclonal antibody (trinbelimab) illustrates typical force values and their consistency across manufacturing batches. The data below was obtained using a UTM per ISO 11040-4 Annex E [4].

Table 1: Break-Loose and Glide Force Profiles for Trinbelimab Prefilled Syringes

Batch Mean Break-Loose Force (First Fmax) Mean Glide Force (Fav) Maximum Force (Fmax) Minimum Force (Fmin)
A (n=19) 3.99 N 1.43 N 5.87 N 0.87 N
B (n=20) 3.83 N 1.45 N 5.31 N 0.88 N
C (n=20) 3.79 N 1.28 N 5.12 N 0.79 N

Analysis of this data demonstrates consistent performance across batches, with break-loose forces below 4 N and steady glide forces around 1.4 N. The design input requirement for this specific 1-mL syringe was that combined forces must not exceed 15 N, a threshold far above the measured values, ensuring a safety margin for usability [4].

The Impact of Viscosity and Needle Design on Injection Time

Injection time is a critical, patient-facing metric directly governed by the interaction of formulation viscosity, needle design, and autoinjector spring force. A study pairing the YpsoMate 2.25 autoinjector with various BD Neopak syringe configurations demonstrates this relationship clearly.

Table 2: Injection Time (seconds) by Viscosity and Needle Configuration

Needle Configuration 11 cP 23 cP 36 cP 53 cP 70 cP
27G UTW 8 mm 3.63 s 7.30 s 11.20 s 16.83 s 22.92 s
27G STW 8 mm 5.10 s 10.05 s 15.67 s 23.77 s 32.57 s
27G STW 12.7 mm 6.08 s 12.57 s 19.87 s 30.43 s 37.45 s
29G ETW 8 mm 8.13 s 16.63 s 26.83 s n/a n/a

UTW: Ultra-Thin Wall; STW: Special-Thin Wall; ETW: Extra-Thin Wall. Data sourced from [49].

Key insights from this dataset include:

  • Viscosity is a primary driver: For any single needle, injection time increases significantly with viscosity.
  • Needle inner diameter is dominant: UTW designs, which have the largest internal diameter for a given gauge, consistently provided the fastest injection times across all viscosities. This aligns with the Hagen-Poiseuille equation, where flow rate is proportional to the fourth power of the radius [49].
  • Needle length is secondary: Longer needles (e.g., 12.7 mm vs. 8 mm) increase flow resistance and time, but to a lesser extent than wall thickness.

Establishing Clinically Relevant Force Thresholds

Translating biomechanical data and user feedback into specific, numerical thresholds is essential for setting Essential Performance Requirements (EPRs) during device development.

The 15 N Usability Threshold

A clearly defined upper limit for injection force is critical. Research and human factors testing indicate that the cumulative force required to activate a device and complete an injection must be low enough for the intended patient population to manage comfortably. Based on user studies and regulatory guidance, a common design input requirement is that the sum of break-loose and glide forces should not exceed 15 N [4]. This threshold ensures that devices are usable by individuals with reduced hand strength, such as those with arthritis or multiple sclerosis, without causing strain or failure to deliver the dose.

The 30-Second Injection Time Benchmark

Beyond pure force, injection duration is a key determinant of patient tolerance and adherence. Clinical studies suggest that subcutaneous injections of up to 2 mL volumes are well tolerated when completed within approximately 30 seconds [49]. This benchmark informs device design, particularly for high-viscosity, high-volume formulations. As shown in Table 2, while a 70 cP formulation with a 27G STW 12.7 mm needle approaches this limit (37.45 s), optimizing to a UTW needle brings the time down to a more comfortable 22.92 seconds.

The following diagram illustrates the logical workflow from patient and formulation needs to the establishment of verifiable force thresholds.

G cluster_0 Key Clinical Thresholds PatientNeeds Patient Needs & Capabilities DeviceDesign Device Design & Integration PatientNeeds->DeviceDesign Formulation High-Viscosity/Volume Formulation Formulation->DeviceDesign ForceMeasurement Standardized Force Measurement (BLEF Test) DeviceDesign->ForceMeasurement DataAnalysis Performance Data Analysis ForceMeasurement->DataAnalysis ClinicalThresholds Establish Clinical Thresholds DataAnalysis->ClinicalThresholds ForceLimit Total Force < 15 N TimeLimit Injection Time ~ 30 s

Advanced Predictive Modeling for Force Thresholds

To accelerate development and mitigate the risk of late-stage failures, advanced modeling techniques are now being employed to predict device performance throughout its shelf life.

  • From BLEF Data to Dynamic Prediction: Traditional constant-speed BLEF tests do not accurately represent the dynamic behavior of a spring-driven autoinjector. Novel software, co-developed by industry leaders, uses a time-stepped model that incorporates BLEF data, spring mechanics, and fluid dynamics (Hagen-Poiseuille equation) to predict injection time distributions and maximum force requirements with high accuracy [29].
  • Accounting for Shelf-Life Ageing: A critical challenge is that desiliconization of syringe barrels over time increases friction. The modeling software incorporates data from aged syringes to forecast end-of-shelf-life performance. This allows developers to work backwards and set maximum allowable BLEF limits at time zero, ensuring the device will still perform after its expiration date [29]. This transforms the development process from a physical "build-and-test" loop to a more efficient mathematical modeling approach, saving significant time and cost.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful experimentation in this field relies on a suite of specialized equipment, materials, and software.

Table 3: Essential Research Toolkit for Injection Force Analysis

Tool Category Specific Item / Example Primary Function
Force Measurement Hardware Universal Testing Machine (e.g., Zwick, Instron) with calibrated load cell Precisely measures force (N) and displacement during plunger actuation.
Primary Container Prefilled Syringe (PFS) with varying needle gauges (e.g., 27G, 29G) and wall types (UTW, STW) The test article for BLEF studies; component performance is critical.
Device Platform Autoinjector (e.g., YpsoMate) Provides the spring force and user interface for integrated system testing.
Formulation Simulants Glycerin/Water solutions at various viscosities (e.g., 11 cP to 70 cP) Simulates the flow properties of biologic drug formulations without using active product.
Data Acquisition & Control testXpert III, Bluehill Software to control the UTM, record force/displacement data, and calculate key metrics.
Auxiliary Sensors High-speed camera, acoustic click detector Visually confirms injection completion and synchronizes auxiliary events with force data.
Predictive Software Custom force-modeling software (e.g., Sanner/Pfizer) Translates BLEF test data into predictions of dynamic autoinjector performance and ageing effects.

Establishing clinically relevant force thresholds is a multidisciplinary process that integrates rigorous standardized testing, quantitative analysis of component interactions, and a deep understanding of patient needs and capabilities. The prevailing thresholds of <15 N for total force and ~30 seconds for injection time provide clear targets for the industry. The emergence of sophisticated predictive modeling tools marks a significant advancement, enabling developers to proactively design robust, patient-centric drug delivery systems that will perform reliably from the first day of manufacture to the last day of their shelf life. As drug formulations continue to grow more complex, these evidence-based approaches to setting and verifying force thresholds will remain central to the successful development of combination products.

The shift of healthcare delivery from clinical to home settings has accelerated the development and adoption of advanced drug delivery systems. Pre-filled syringes, autoinjectors, and on-body devices represent key technologies enabling this transition, particularly for biologic drugs and chronic conditions. Each system offers distinct advantages and limitations regarding usability, technical complexity, formulation requirements, and patient experience. This comparative analysis examines these three delivery platforms within the context of injection force measurement, a critical parameter influencing device performance and patient acceptance. Understanding the interplay between device mechanics, formulation properties, and physiological constraints is essential for researchers and drug development professionals selecting optimal delivery strategies for specific therapeutic applications.

Technical Comparison of Delivery Systems

The table below summarizes the core characteristics of the three drug delivery systems, highlighting key differentiators that inform device selection during development.

Table 1: Technical Comparison of Pre-filled Syringes, Autoinjectors, and On-Body Devices

Parameter Pre-filled Syringe (PFS) Autoinjector On-Body Device (OBD)
Typical Volume Range Up to 3 mL (newer formats: 5 mL) [72] [53] Typically < 2-3 mL (large-volume: ≥5 mL in development) [72] [53] 2 mL to 20+ mL [72] [53]
Administration Method Manual injection by user or HCP Spring- or gas-powered automated injection Wearable, pump-driven infusion over minutes to hours [53]
Key Technical Challenge Glide force consistency, silicone oil stability [29] High-power mechanism reliability, flange breakage risk [30] [53] Adhesive failure risk, occlusion, incomplete dosing [53]
Injection Force & Viscosity Human-powered; limited by user capability Spring/gas force must overcome high viscosity; higher power needs for large volumes [53] Lower, sustained force; can handle high viscosity over extended time [72]
Patient Experience & Usability Direct needle visualization; requires training [73] Hidden needle; auditory/tactile feedback; high usability (91-97% positive response) [73] [30] Hands-free; minimal dexterity needed; ideal for extended delivery [72]
Formulation & Stability Subject to brief high-shear stress; silicone oil interaction risk [72] Similar to PFS; high concentration/viscosity challenges [72] Must remain stable at skin temperature for hours [72]

Experimental Data and Performance Metrics

Usability and Human Factors Data

Direct comparative studies between these delivery systems provide valuable performance data. In an open-label, 12-month study comparing an investigational autoinjector and a prefilled syringe for galcanezumab delivery, patient-rated experiences were assessed using the Subcutaneous Administration Assessment Questionnaire (SQAAQ). The vast majority of patients (91–97%) provided positive responses across all assessed items for the autoinjector, indicating high usability [73]. The study found no statistically significant differences in pharmacokinetic parameters (AUC and Cmax) between the two devices, demonstrating comparable bioavailability [73]. For injection-site adverse events, 23 events were recorded with the first self-administered injection, with no significant differences between the prefilled syringe (N=7) and autoinjector (N=16; P=0.061) [73].

Injection Force and Viscosity Performance

Injection force represents a critical performance parameter directly impacted by formulation viscosity and device mechanics. Experimental data and modelling reveal significant differences between delivery systems.

Table 2: Injection Force and Viscosity Tolerance Across Delivery Systems

Device Type Maximum Viscosity Handling Injection Time Key Force-Related Challenges
Pre-filled Syringe Limited by manual user force User-dependent (typically <30 sec) Break-loose and extrusion force (BLEF) variability; desiliconization over shelf-life [29]
Autoinjector Up to 5,000 cP for specialized gas-powered devices [53] 5-30 seconds (longer for large volumes) High power requirements; spring force degradation; syringe flange breakage risk [30] [53]
On-Body Device Can handle high viscosity via extended infusion time [72] Minutes to several hours Consistent, low-force delivery; back-pressure from tissue resistance [53]

For pre-filled syringes, Break-Loose and Extrusion Force (BLEF) testing according to ISO 11040-8 is a standard methodology for characterizing performance. This test involves using a tensometer to drive a plunger at constant speed while measuring the varying force as it moves down the syringe barrel, capturing the initial break-loose force, dynamic extrusion force, and any air bubble expulsion [29]. Research indicates that shortening needle length from traditional 12.7mm to 8mm can reduce injection force by approximately 25%, offering a significant improvement for viscous formulations [74].

Methodologies for Injection Force Measurement

Standardized Testing Protocols

Robust measurement of injection forces is essential for device development and validation. Standardized testing frameworks ensure consistent performance evaluation across different platforms. Key standards include:

  • ISO 11040-4 & -8: Define requirements for testing pre-filled syringes, including break-loose glide force and flange breakage force, the latter being critical for autoinjectors where the syringe flange absorbs reaction forces during activation [30].
  • ISO 11608 Series: Outlines requirements for needle-based injection systems, including autoinjectors.
  • USP <382> & <1382>: Provide guidance on elastomeric components and single-use systems.

Advanced testing systems integrate multiple sensors to capture essential drug delivery outputs (EDDOs). These systems now often include precision balances for volume delivery accuracy per ISO 11040-8, acoustic sensors for auditory click detection to confirm device activation and completion, and cameras to visually document drug delivery confirmation through windows in autoinjectors [30].

Advanced Force Modeling

Given the risk of device failure late in development, particularly after shelf-life aging, advanced modeling approaches are becoming crucial. A novel software solution co-developed by Sanner Group and Pfizer's Devices Centre of Excellence uses a time-stepped computational model to predict device performance from BLEF test data [29]. This model accounts for complex dynamic interactions between spring force, plunger speed, syringe pressure, and fluid dynamics via the Hagen-Poiseuille equation, including the challenging factor of air bubble compression [29]. The methodology uses desiliconized syringes as a worst-case scenario for aging studies and employs Monte Carlo sampling to account for parameter variances, enabling developers to specify maximum allowable BLEF limits at time zero that ensure performance after shelf-life expiration [29].

InjectionForceModeling BLEFData BLEF Test Data (Constant Speed) TimeStepModel Time-Stepped Model BLEFData->TimeStepModel ModelInputs Device Parameters & Tolerances MonteCarlo Monte Carlo Sampling ModelInputs->MonteCarlo PerformancePred Performance Predictions (Injection Time, Force) TimeStepModel->PerformancePred AgingSim Aging Simulation (Desiliconization) TimeStepModel->AgingSim MonteCarlo->TimeStepModel SpecLimits Specification Limits (Max Allowable BLEF) AgingSim->SpecLimits

Figure 1: Workflow for predictive modeling of injection device performance using BLEF test data and Monte Carlo sampling to account for variances, culminating in specification limits that ensure performance after shelf-life aging.

The Scientist's Toolkit: Research Reagents and Materials

Successful development and testing of injection devices require specialized materials and measurement tools. The following table details essential components for researchers working in this field.

Table 3: Essential Research Materials for Injection Device Development

Item Function/Application Key Considerations
Tensometer/Universal Tester Measures break-loose and extrusion forces (BLEF) on syringes and autoinjectors [30] [29] Must comply with ISO 11040-4/-8; capable of integrating additional sensors (acoustic, visual) [30]
Pre-filled Syringes with 8mm Needles Testing reduced injection force for viscous biologics [74] ~25% force reduction vs. 12.7mm needles; requires compatible rigid needle shields [74]
Cross-linked Siliconized Barrels Mitigates desiliconization and protein aggregation risks [72] Reduces silicone oil leaching; improves formulation stability and consistent glide forces [72] [29]
Placebo Formulations (Varying Viscosity) Simulating drug product behavior during device testing Should match rheological properties of active drug; enables device testing without active ingredient
Acoustic Click Detection System Validates auditory feedback mechanisms in autoinjectors [30] Integrated with force testing; confirms start/end of injection for usability
Aging Chambers Accelerated stability studies for device components Simulates shelf-life effects on silicone lubrication and plastic components [29]

Pre-filled syringes, autoinjectors, and on-body devices each occupy distinct niches in the drug delivery landscape, guided by their technical capabilities and limitations. Pre-filled syringes offer simplicity and cost-effectiveness but require user training and dexterity. Autoinjectors significantly enhance usability and patient acceptance for volumes up to approximately 2-3 mL, but face power and mechanical challenges with larger, more viscous formulations. On-body devices excel in delivering large volumes and high-viscosity drugs with minimal patient intervention, albeit at higher complexity and cost. Injection force remains a fundamental parameter connecting formulation properties with device design and patient experience. Advanced modeling and standardized testing methodologies, including BLEF analysis and predictive software, are becoming indispensable tools for optimizing these systems. Future advancements will likely focus on overcoming viscosity barriers, improving connectivity for adherence monitoring, and further personalizing device ergonomics to meet diverse patient needs across therapeutic areas.

Validating Predictive Models Against Real-World Device Performance Data

For researchers and drug development professionals, the accuracy of injection force predictive models is critical for designing patient-centric drug-device combination products, such as prefilled syringes and autoinjectors. These models must be validated against real-world device performance data to ensure they accurately simulate the forces patients encounter during subcutaneous or intramuscular administration. Discrepancies between predicted and actual performance can significantly impact usability, dose accuracy, and ultimately, patient safety and adherence. This guide examines the current methodologies for model validation and objectively compares the performance of various predictive approaches against experimental data, providing a structured framework for evaluating model robustness in the context of injection force measurement research.

Comparative Analysis of Predictive Model Performance

Experimental Injection Force Data from Prefilled Syringes

The following table summarizes real-world injection force data obtained from testing three validation batches of a monoclonal antibody (trinbelimab) in 1 mL prefilled syringes, measured using a universal testing machine (UTM) according to ISO 11040-4 guidelines [4].

Table 1: Measured Break-Loose and Glide Forces for Trinbelimab Prefilled Syringes

Batch Identifier Sample Size (n) Mean Break-Loose Force (First Fmax, N) Mean Dynamic Glide Force (Fav, N) Maximum Force (Fmax, N) Minimum Force (Fmin, N)
Batch A 19 3.99 1.43 6.10 0.69
Batch B 20 3.83 1.45 5.92 0.70
Batch C 20 3.79 1.28 5.51 0.61

This empirical data establishes a performance baseline, demonstrating consistent break-loose and glide forces across manufacturing batches. The break-loose force (the peak force required to initiate plunger movement) and dynamic glide force (the average force to sustain movement) are Critical Quality Attributes (CQAs) and Essential Performance Requirements (EPRs) for combination products [4].

Predictive Model Performance Comparison

The table below compares the predictive accuracy of a newly developed advanced model against a traditional Hagen-Poiseuille based model, using experimental data as the ground truth [1].

Table 2: Comparison of Predictive Model Accuracy Against Experimental Data

Model Characteristic Traditional Hagen-Poiseuille Model Advanced Integrated Model
Core Mathematical Foundation Basic Hagen-Poiseuille equation [1]. Refined Hagen-Poiseuille law integrated with a friction force component [1].
Rheological Behavior Handling Assumes Newtonian fluid behavior only [1]. Accommodates both Newtonian and shear-thinning (non-Newtonian) fluids [1].
Temperature Considerations Often uses standard lab temperature, neglecting real-world variability. Incorporates the actual temperature of injection during administration [1].
Tissue Counter-Pressure Typically performed in-air, ignoring biological tissue resistance. Accounts for tissue back-pressure generated at the injection site [1].
Reported Prediction Accuracy Shows significant deviation from measured forces, especially for mAbs [1]. Demonstrates superior performance in accurately predicting injection force for mAbs [1].
Key Limitation Inaccurate risk assessments during design input [1]. Enables more reliable specification setting for PFS and autoinjector development [1].

The advanced model's integration of friction force, shear-thinning rheology, and in-use environmental factors like temperature and tissue pressure allows it to closely mirror real-world injection dynamics, reducing the risk of late-stage design changes [1].

Experimental Protocols for Validation

Standardized Force Measurement Protocol

Validating predictive models requires generating high-fidelity experimental data. The following protocol, adapted from ISO 11040-4, details the essential steps [4].

  • Apparatus Setup: Use a Universal Testing Machine (UTM) equipped with a calibrated load cell (e.g., 200 N capacity, accuracy class 0.5 per ISO 7500-1) and a specialized fixture to hold the syringe barrel securely [4].
  • Sample Preparation: Condition prefilled syringes to the specified testing temperature (e.g., room temperature or a simulated use temperature) to account for viscosity variations [1].
  • Mounting: Carefully remove the needle shield and mount the syringe in the UTM fixture. Position the machine's crosshead to make contact with the plunger rod's end.
  • Test Parameters: Set the plunger displacement speed to a clinically relevant rate (e.g., 50 mm/min) and define the plunger travel distance (e.g., 18.2 mm for a 1 mL syringe) [4].
  • Data Acquisition: Initiate the test. Software (e.g., testXpert III) automatically records the force-displacement profile and calculates key parameters [4]:
    • Break-loose force: The maximum force (first Fmax) observed during the initial 0-2 mm of plunger travel.
    • Glide force: The average force (Fav) required over the sustained travel distance (e.g., 2-18.2 mm).
  • Statistical Analysis: Test a statistically appropriate sample size (e.g., n=20 per batch). Perform Gage Repeatability and Reproducibility (R&R) studies to validate the measurement system and use statistical software (e.g., JMP SAS) to analyze intra- and inter-batch consistency [4].
Protocol for Human Factor Validation

Beyond mechanical testing, understanding human capability is paramount. A typical human factors validation protocol involves [1]:

  • Recruitment: Recruit study participants representative of the target patient population, including individuals with conditions that may impair hand strength (e.g., rheumatoid arthritis, elderly patients).
  • Strength Assessment: Measure the maximum thumb or finger push strength of participants using standardized methods.
  • Usability Testing: Participants use the device (e.g., prefilled syringe) to inject into a simulated tissue medium or a placebo formulation.
  • Data Collection: Record the success rate of complete dose delivery, subjective feedback on ease of use, and any difficulties encountered.
  • Analysis: Correlate the measured injection forces from mechanical testing with the human strength data and usability outcomes. This defines the upper limit for injection force specifications to ensure the device is usable by the entire target population [1].

Visualization of the Model Validation Workflow

The following diagram illustrates the integrated workflow for developing and validating an injection force predictive model, highlighting the continuous feedback loop between prediction and real-world measurement.

InjectionForceValidation Injection Force Model Validation Workflow ModelInputs Model Inputs PredictionEngine Prediction Engine (Advanced Mathematical Model) ModelInputs->PredictionEngine FluidProps Fluid Properties (Viscosity, Rheology) FluidProps->ModelInputs DeviceParams Device Parameters (Syringe size, Needle gauge) DeviceParams->ModelInputs UserFactors User & Environment (Injection speed, Temperature) UserFactors->ModelInputs ForcePrediction Predicted Injection Force Profile PredictionEngine->ForcePrediction Validation Model Validation & Comparison ForcePrediction->Validation RealWorldData Real-World Data Collection (UTM Testing, Human Factors) PerformanceOutput Measured Force Profile (Break-loose, Glide force) RealWorldData->PerformanceOutput PerformanceOutput->Validation DesignLoop Refine Product Design & Update Model Validation->DesignLoop If Deviation > Threshold DesignLoop->ModelInputs

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials and Equipment for Injection Force Research

Item Function & Application in Research
Universal Testing Machine (UTM) A Zwick or equivalent UTM with a high-accuracy load cell is the core instrument for measuring break-loose and glide forces according to international standards [4].
Prefilled Syringes (PFS) The primary test article for injectability studies. Components (plunger, stopper, glass barrel, needle) and their quality (e.g., siliconization level) directly impact force profiles [4].
Model Biologic Solutions Protein formulations (e.g., monoclonal antibodies) and viscosity standards (e.g., PEG, CMC solutions) are used to understand the impact of fluid rheology (Newtonian vs. shear-thinning) on injection forces [1].
Data Processing Software Software like testXpert III or JMP SAS is used to control the UTM, automatically extract force parameters (Fmax, Fav, Fmin), and perform statistical analysis for process consistency and model validation [4] [1].
Human Factors Panels Recruited panels of healthy adults and target patient populations (e.g., with rheumatoid arthritis) are essential for validating that device forces are within comfortable and achievable limits for end-users [1].

The validation of predictive models against robust, real-world device performance data is a cornerstone of modern drug-device combination product development. As demonstrated, advanced models that integrate comprehensive inputs—including fluid rheology, friction forces, and in-use environmental variables—show markedly superior accuracy in predicting injection forces compared to traditional models. The consistent application of standardized mechanical testing protocols, coupled with human factors validation, ensures that these models are not only mathematically sound but also clinically relevant. For researchers, this rigorous validation framework is indispensable for de-risking development, informing design spaces, and ultimately delivering drug delivery systems that are reliable, safe, and acceptable to patients.

Conclusion

Injection force measurement is a cornerstone of developing successful, patient-centric drug delivery systems, especially for complex biologics and microparticle formulations. A comprehensive approach that integrates foundational principles, advanced predictive modeling, robust testing methodologies, and human factor validation is essential. The future of the field lies in smart, connected systems that can adapt to formulation challenges, with ongoing innovation in predictive tools and device technology being critical for accelerating the development of safe, effective, and patient-friendly therapies.

References